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Abstract 
Background: 
Previous reports described activation of the haemostatic mechanism in patients 
with abdominal aortic aneurysm (AAA). Both open and endovascular repair of 
AAA have been found to affect the haemostatic markers. Cystatin C is an 
endogenous marker of renal function that may be more sensitive for detecting 
mild to moderate reduction in glomerular filtration rate (GFR). High cystatin C has 
been shown to be strongly associated with cardiovascular outcomes in different 
clinical scenarios. 
Aim: 
To establish the medium term effects of endovascular and open aneurysm repair 
on coagulation and fibrinolysis. In addition to that, to explore the effect of 
endovascular repair on renal function using Cystatin C.  
Patients and Methods:    
Twenty-nine patients completed the twelve months follow up after endovascular 
aneurysm repair (EVAR), eleven patients were recruited after they had open 
aneurysm repair (OAR) and eight age-matched control (AMC) without AAA, as 
documented by CT scan, were recruited. Patients were tested for markers of 
coagulation, fibrinolysis and renal function pre-operatively and at 1, 6 and 12 
months post-operatively. 
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Results:  
Pre-operatively, PF1+2 levels were significantly higher in patients with AAA than 
in AMC. PF1+2 levels post-EVAR and post-OAR were significantly lower than 
pre-operative values and similar to AMC. There was no significant difference in 
TAT, PAI, or t-PA between AMC, AAA preoperatively, and post-EVAR. Post-
OAR, PAI activity was significantly higher than in pre-operative patients.  
At 24 hours after procedure, a significant increase in Cystatin C and serum 
creatinine (sCr) and significant decrease in eGFR were seen. Cystatin C 
continued to increase and was significantly higher at 1, 6 and 12 months. 
Cystatin C increased significantly post-operatively regardless of the baseline 
renal function. None of the patients required renal replacement therapy. 
Conclusion:  
AAA is associated with increased thrombin generation without up-regulation of 
fibrinolysis. The pro-thrombotic, hypo-fibrinolytic diathesis observed in patients 
with AAA returns toward normal in the medium term after EVAR and OAR.  
EVAR is associated with a significant increase in Cystatin C starting 24 hours 
after the procedure and is maintained for 12 months. sCr and eGFR only show 
significant change at 24 hours and therefore may underestimate long-term renal 
damage after EVAR.  
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Chapter 1 
General background 1 
1.1 Abdominal Aortic Aneurysm: Prevalence and risk of rupture: 
Abdominal Aortic Aneurysm (AAA) is a leading cause of death worldwide. In the 
United States (US), AAA occurs in an estimated 5%–7% of the population older than 
60 years of age, often as an unrecognized disease.(1) The prevalence of AAA may 
be falling in the United Kingdom (UK); however, the condition remains relatively 
common in patients over the age of 65 years.(2)  AAA often remain asymptomatic 
and undetected until rupture occurs and, despite advances in surgical and 
anaesthetic techniques, most patients with ruptured AAA die of the condition, often 
before they reach hospital.(3)  
The risk of aneurysm rupture is related to AAA diameter and repair is indicated in 
aneurysms measuring 5.5 cm or more.(2) This is because the risk of aneurysm 
rupture is higher for AAA more than 5.5 cm in diameter.(4) Aneurysm rupture 
accounts for 4000 deaths every year in England and Wales.(5) AAA is the 15th 
leading cause of death overall in the United States and the 10th leading cause of 
death in men older than age 55, with approximately 9,000 AAA-related deaths 
occurring annually.(1, 6) 
The presence of an AAA is strongly associated with atherosclerotic cardiovascular 
disease (CVD).(7) The latter is primarily responsible for the annual mortality rate of 
5% in men with a small AAA.(4) The cardiovascular risk is both proportional to aortic 
diameter and independent of baseline CVD and conventional atherosclerotic risk 
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factors.(8-10) The risk of death in men with a small AAA principally relates to CVD, 
not aortic rupture. The nature of this risk is currently unexplained.  
There is an association between deranged haemostatic markers and cardiovascular 
morbidity. Activated coagulation leads to the development of micro-vascular and 
macro-vascular thrombosis resulting in myocardial infarction, multiple organ failure 
and thrombo-embolism.(11-13) The level of coagulation dysfunction is related to old 
age, smoking and the presence of peripheral atherosclerosis.(14-16) 
Previous studies found activation of the haemostatic mechanism in patients with 
AAA.(17-19) This has been found to correlate with aneurysm size.(20) However, high 
fibrin turnover was found in patients with small abdominal aortic aneurysm as well. 
The intra-mural thrombus plays an important role in maintaining the coagulation 
activity through fibrin generation and turnover in the thrombotic mass.(21) Positive 
correlation was found between the thickness of the thrombus in AAA and activation 
of blood coagulation and fibrinolysis activity.(12, 13, 22) 
Major surgery results in a peri-operative pro-thrombotic diathesis as well as 
deranged fibrinolysis and platelet hyperactivity. This results in elevated levels of 
factor VIII, fibrinogen, thrombin-antithrombin III-complex (TAT) and Von-Willebrand 
factor (vWF).(23-28) Patients undergoing elective open infra-renal AAA repair have 
an associated operative mortality rate of 3-10%.(29-33) The majority is probably 
secondary to micro- and macro- vascular thrombosis causing myocardial injury, 
thrombo-embolism and multiple organ failure.(34) 
The Abdominal Aortic Aneurysm Quality Improvement Programme (AAAQIP) was 
initiated after the UK was found to have a high outlying mortality rate for AAA surgery 
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at 7.9%, compared to the rest of Europe at 3.5%. The aim was reducing elective 
AAA mortality in the U.K to 3.5% by 2013. 
 
1.2 Endovascular Aneurysm Repair: 
EVAR was first performed by the Ukrainian surgeon Nicholas Volodos in 1987. 
However, it was the publication by Juan Parodi in 1990 (35) that EVAR had been 
widely promoted as providing a less invasive and safer alternative treatment option 
to conventional open repair of AAA, especially in the high risk patients. It is now well 
established, following the publications of EVAR-1, EVAR-2, DREAM, OVER and 
ACE trials, that endovascular repair of AAA reduces operative mortality by 
approximately 60% compared with open surgical repair in the fit and anatomically 
suitable patient.(36-41) 
However, EVAR have been found to promote a systemic inflammatory response and 
pro-thrombotic coagulopathy equal if not greater than that witnessed after open 
surgical repair. It has been suggested that this could be secondary to cytokine 
release from thrombus within the aneurysm sac either as a result of the introducer 
and catheter manipulation or, possibly, ischaemia after AAA exclusion.(42-44) 
Exponents have argued that the initial operative mortality benefits encountered with 
EVAR are offset by the long term economic cost due to secondary technical 
complications.(45) 
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1.3 Endoleak: 
Endoleak is the outflow and leak of blood outside the endovascular stent graft but 
still within the aneurysm sac.(46) It is a specific complication to EVAR and results in 
restoring blood flow within the aneurysm sac resulting in perfusion of the aneurysm 
sac with the subsequent risk of rupture. The majority of cases are caused by the 
back flow from the IMA and/or lumbar arteries leading to incomplete exclusion of the 
sac form the systemic circulation. The long term outcome and durability of EVAR are 
dependent on the incidence and type of endoleak as well as graft migration. Both 
complications are the most common complications after EVAR and could represent 
an obstacle to establish EVAR as a durable alternative treatment option to open 
surgical aneurysm repair.(47) The EVAR-1 trial reported 22% (118 cases) of EVARs 
were complicated by endoleak and 35% required a secondary procedure to maintain 
complete aneurysm exclusion within 3 years of the procedure. A systemic review by 
Drury et al reported 17.5% and 21.3% of all EVAR procedures demonstrated 
endoleak at 30 days and 12 months respectively.(48) 
1.3.1 Types of Endoleak: 
Endoleak is classified into five types according to the source of blood leak inside the 
aneurysm sac that causes continued perfusion of the aneurysm sac.  
1.3.1.1 Type I endoleak  
This occurs due to inadequate seal at the top and/or the bottom of the stent graft to 
the aortic or iliac artery wall. If there is inadequate fixation at the proximal end, this 
represents type IA and if the leak occurs at the distal end of the stent graft, this 
indicates type IB. This leads to continued sac perfusion as a result of the inadequate 
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fixation and seal resulting in increasing the pressure inside the aneurysm sac. This 
type of endoleak is dangerous and inevitably requires further intervention as it 
carries high risk of aneurysm sac rupture as it seldom resolves spontaneously. In the 
majority of cases, endovascular intervention is usually enough to correct the 
problem. However, if endovascular treatment is not feasible, open surgical 
intervention may be necessary. 
1.3.1.2 Type II endoleak  
This is the most common type and it is considered a benign condition. The 
continuous perfusion of the residual AAA sac occurs due to leak from one or more 
patent vessels that normally arise from the abdominal aorta. Lumbar arteries are the 
most common source of type II endoleak. However, inferior mesenteric artery (IMA) 
is identified as another source of this kind of endoleak. Back flow of arterial blood 
through a patent artery inside the aneurysm sac provides the inflow to the residual 
AAA sac. If there is another patent artery, it serves as the outflow vessel. The 
majority of type II endoleak do not require intervention as they do not result in 
increase in the sac pressure or size and they usually resolve spontaneously. Sildof 
et al has concluded that rupture secondary to an isolated type II endoleak is rare (< 
1%), but over a third occur in the absence of sac expansion. Translumbar 
embolization has a high success rate in treating this type of endoleak.(49, 50) 
1.3.1.3 Type III endoleak  
It occurs when there is disarticulation or separation of one or more modular 
components of the stent-graft. It also happens due to fracture of the stent graft 
resulting in significant reperfusion of the residual aneurysm sac. This could be due to 
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a functional fault of the graft or insufficient seal between the different stent grafts 
used to exclude the aneurysm sac. This type does require urgent treatment due to 
the high risk of aneurysm rupture associated. It does not resolve spontaneously and 
endovascular intervention is the usual and most successful treatment option.  
1.3.1.4 Type IV endoleak  
This type is significantly less common than it has been in the past as a result of 
manufacturer improvements in fabric composition. It results from high porosity of the 
graft fabric that causes leak of blood through the fabric resulting in perfusion of the 
residual sac. This type usually occurs once the stent graft is inserted and it usually 
settles within days and seldom requires further intervention.  
 1.3.1.5 Type V endoleak   
This type is also known as endotension. It happens when there is continuous 
expansion of the residual aneurysm sac in absence of an identifiable source of 
endoleak. In this type, no endoleak is identified through the available imaging 
modalities. Despite that, the aneurysm sac continues to increase in size. Some 
believe this type is actually one of the previous four types while there is failure in 
demonstrating the type and source of the endoleak.(47) Failure of the detection of 
the endoleak by the available imaging tools with the continuous perfusion of the sac 
result in high pressure within the sac with the increase in size.(51, 52) Other 
explanations include filtration of serous fluid ultra-filtrate through the graft fabric back 
into the aneurysm sac.(53, 54) The treatment of type V endoleak depends on the 
cause and it is individualized.  
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1.4 Surveillance after EVAR: 
Long term surveillance of patients following EVAR is essential for (i) detection and 
characterization of endoleak; (ii) detection of increase or decrease of the residual 
aneurysm sac by measuring the aneurysm sac size and detection of significant 
alteration in aneurysm sac dimensions; (iii) detection of mechanical complications of 
the stent-graft, such as migration, kinking, or fracture; and (iv) assessment of the 
long-term outcome and performance of the stent grafts.  
At present contrast-enhanced spiral Computerised Tomography angiography (CTA) 
scan with specialized 3D reconstruction is considered as the gold-standard for 
endoleak surveillance.(55) CTA is efficient in defining the anatomy of aneurysm sac, 
detection of endoleak and its classification. However, factors such as a high dose of 
radiation with risk of malignancy (56), administration of nephrotoxic contrast (57) and 
high cost (58) are the main limitations of its use as a lifelong surveillance tool. For 
these reasons the short term peri-operative mortality/morbidity benefits of EVAR may 
be outweighed by its long term economic and resource burden to the institution, in 
addition to the increased risk of malignancy associated with frequent x-ray exposure. 
Duplex ultrasound is being investigated as an alternative to CT for the follow-up of 
EVAR patients. This modality is less expensive and does not carry the risks 
associated with ionizing radiation or contrast induced nephrotoxicity. Duplex 
ultrasound with non-nephrotoxic contrast agents have been used to detect post-
EVAR endoleak.(59, 60) In their meta-analysis, Mirza et al found that the 
unenhanced duplex ultrasound has poor sensitivity for endoleak detection; however 
contrast enhanced ultrasound (CEUS) is a highly sensitive modality.(61) 
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Despite the advancement in imaging modalities to follow up EVAR, plain radiography 
continues to be used in basic post-EVAR surveillance. Some still believe that plan X-
ray is superior to CT for demonstrating the conformation of thoracic stent-grafts (62) 
and for detection of kinks in abdominal stent-grafts.(63) Plain X-ray usually requires 
four views to cover all the angles of the stent grafts. Antero-posterior and lateral 
pictures can identify stent-graft migration and component separation and oblique 
radiographs may detect of stent fracture. However, plain radiography does not have 
any role in diagnosis or identification of endoleak or sac expansion. 
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1.5 Supra-renal Fixation of EVAR: 
Successful EVAR requires proximal seal of the endograft to prevent stent migration 
and Type 1a endoleak. Unfavourable features of the infra-renal aortic neck, e.g. 
severe angulation, short neck length, cone shaped neck, presence of thrombus or 
calcification, may adversely affect the long term outcome of EVAR.(64) To overcome 
the unfavourable morphological anatomy of infra-renal neck, supra-renal (SR) 
fixation has been proposed as an option to provide safe and more secure form of 
proximal fixation which will lead to increase the number of patients eligible for 
standard EVAR. SR-EVAR shows bare stents crosses the renal arteries in 
comparison to infra-renal (IR) fixation in which no stents crosses the renal 
arteries.(65)  
Dilatation of the infra-renal neck, which could lead to endograft migration, has been 
reported following EVAR.(66-73) The advantage of SR-EVAR is providing more 
durable fixation in the supra-renal portion of the aorta. This part of the aorta is less 
susceptible to aneurysm disease.(74, 75) Although several studies have reported the 
effectiveness of SR-EVAR (76-79), concern persists regarding the long term effect 
on renal function and the patency of renal arteries when the renal artery origins are 
crossed by the bare stents. Miller et al conducted a systematic review and meta-
analysis of 21 studies representing more than 4000 patients to determine the effect 
of SR-EVAR and IR-EVAR on renal function. They concluded that there is no risk of 
post-operative following both modalities especially with the newer devices. They 
suggested long term studies to look at the long term effect of supra-renal fixation on 
renal function. (80) 
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1.6 Fenestrated EVAR: 
Juxta-renal AAAs are those with either a very short or no infra-renal neck. A 
suprarenal cross-clamp would be needed to enable open repair of the AAA with or 
without implantation of one or more renal arteries. Data from the European 
Collaborators on Stent–graft Techniques for Aortic Aneurysm Repair (EUROSTAR) 
registry indicate that EVAR for aneurysms with an infra-renal neck length of less than 
15 mm are associated with a significantly increased risk of proximal endoleak.(81) 
The minimum length of good-quality infra-renal aortic neck necessary to secure a 
safe and durable seal is 10 mm. Therefore, in the endovascular era, a juxta-renal 
aortic aneurysm could be redefined as an aneurysm with an infra-renal neck of less 
than 10 mm. In order to achieve endovascular proximal seal in juxta-renal AAAs, the 
use of a customized stent-graft design including fenestrations for the aortic side 
branches above such a short neck (i.e. the renal arteries and the superior 
mesenteric artery) is necessary. This enables the first sealing portion of the stent-
graft to be positioned in a more stable part of the aorta with the customized 
fenestrations at the exact origin of the targeted vessels. This approach, Fenestrated 
EVAR (F-EVAR), makes it possible to treat patients with short necks and perhaps 
patients with juxta-renal aneurysms.(82-84) A number of published series have 
demonstrated excellent early and mid-term results of the technique and confirmed 
the potential lower peri-operative mortality of the technique in comparison with open 
repair. However, these studies acknowledge the lack of longer-term data.(85-91)  
Another group of patients, who benefit from F-EVAR, are the patients who develop 
complications following open aneurysm repair (OAR) or EVAR. These complications 
include true juxta-anastomotic aneurysms and pseudo-aneurysms following open 
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repair and type I endoleak following EVAR.(92-94) These complications carry 
significant risk of rupture and subsequent mortality if left untreated.(93) In one series 
of patients with para-anastomotic aneurysms (PAA), emergency repair resulted in a 
24% mortality, repair after rupture in 67% mortality, and elective repair carried an 
11% mortality.(95) The utilization of F-EVAR and branched EVAR (B-EVAR) has 
increased the percentage of patients with PAAs after open surgery that could be 
offered an endovascular treatment option. However, the unique difficulties of 
increased graft on graft friction hindering placement, short working distance, and 
increased patient co-morbidities should be recognized.(96, 97) 
One series reported their 8-year experience of F-EVAR with one hundred patients 
treated during the study period with median follow-up 24 months.  This included 16 
patients after previous open surgery or EVAR. Thirty-day mortality and intra-
operative conversion to open repair was 1% for each. Operative visceral vessel 
perfusion rate was 98.9%. Twenty-two patients died during follow-up, all aneurysm 
unrelated. No aneurysm ruptured. Cumulative visceral branch patency was 93.3 ± 
1.9% at 5 years. Visceral artery stent occlusions all occurred within the first 2 
postoperative years. Four renal artery stent fractures were observed, of which three 
were associated with occlusion. Twenty-five patients had an increase of serum 
creatinine (sCr) of more than 30%; two of them required dialysis.(98) 
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Chapter 2 
General Background 2 
2.1 Normal Haemostasis:  
Haemostasis enables an organism to (i) close off damaged blood vessels, (ii) keep 
the blood in a fluid state, and (iii) remove blood clots after restoration of vascular 
integrity. The haemostatic system is highly conserved machinery in which blood 
clotting, also referred to as coagulation, has a prominent role.(99) 
Normal circulation requires the blood to flow in a fluid state in equilibrium not to be 
very thin with the risk of spontaneous bleeding and not thick to develop blood clot. 
The normal haemostatic response to vascular injury is the development of clot to 
seal the site of injury and stop the bleeding. With vascular injury, there is damage to 
the endothelium that activates the coagulation cascade. First, there is adhesion of 
the platelets to the endothelium leading to the formation of platelet plug, at the site of 
injury, and the formation of fibrin mesh on top of that plug. The migration of 
leukocytes to the site of vascular injury is facilitated by chemokines to protect the 
wound from infection and aides in the healing process. The fine line between 
formation of clot to seal the vascular injury in normal healthy individuals and the 
excessive formation of clot causing thrombo-embolic complications should be 
continuously regulated.  
The normal endothelium is anti-thrombotic. However, at the site of injury, tissue 
factor is released causing activation of the coagulation cascade resulting in the 
formation of fibrin. At the same time, the fibrinolytic mechanism is activated to limit 
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the deposition of fibrin to the site of injury, blocking excessive activation of the 
coagulation cascade.  
Dys-regulation of the haemostatic mechanism is the main drive of thrombus 
formation. There are many factors that can contribute to the over expression of the 
coagulation enzymes including genetic and environmental factors.(100) 
 
2.2 The Blood Coagulation Cascade:  
The coagulation cascade is formed of two main pathways. The intrinsic pathway 
which is also known as the contact pathway and the extrinsic pathway which is 
called the tissue factor (TF) pathway (Figure 1). Recent evidence has disputed the 
formerly believed idea of equal importance of the two pathways. The main function of 
the intrinsic (contact) pathway is to augment the coagulation cascade stimulated by 
the TF pathway. The activation of factor IX can be achieved by both pathways.  
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Figure 1:	Coagulation cascade. 
APC, Activated protein C; APC-PCI, activated protein C-protein C inhibitor complex; 
ATIII, antithrombin III; F1+2, prothrombin fragments 1+2; FM-F, fibrin monomer-
fibrinogen complex; Plt, platelets; PS, proteins; SP-selectin, soluble P-selectin; TF, 
tissue factor; TM-IIa, thrombo-modulin-thrombin complex; TAT, thrombin-
antithrombin complex; vWF, von Willebrand factor. 
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2.2.1 Extrinsic/tissue factor pathway: 
TF, which is an active cofactor, triggers the extrinsic pathway when it comes in 
contact with plasma containing activated or inactive factor VII.(101) TF is not 
produced inside cells that come in contact with plasma except at time of vascular 
injury. Then TF can bind to factor VII resulting in the production of TF-VIIa complex. 
When attached to the cell membrane, this complex is a powerful activator of the 
coagulation cascade. Furthermore, TF can produced by monocytes and smooth 
muscle cells in response to cytokines and inflammatory mediators.(102)  
Factor VII is a typical vitamin-K-dependent plasma protein that is produced in the 
liver. The vast majority of factor VII is inactive with only 1% is present as an activated 
factor VIIa which is a weak enzyme when not part of the TF-VIIa complex. Factor VII 
abundance has been linked with thrombotic conditions, while its deficiency is a rare 
condition in which major bleeding could happen (103-107)  
A recombinant activated human factor VII produced by transfection of the human 
factor VII gene is available (Novo-Seven). Its indication is for promoting haemostasis 
in individuals with haemophilia who have antibody inhibitors to coagulation factors 
VIII or IX, patients with acquired haemophilia, patients with congenital factor VII 
deficiency and for treatment Glanzmann's thrombasthenia. 
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2.2.2 Intrinsic/Contact pathway: 
The intrinsic pathway is activated when blood comes into contact with a negatively 
charged surface resulting in the activation of factor XII. Despite that, factor XII 
deficiency is not associated with bleeding and may even be associated with 
thrombosis.(108) The intrinsic pathway causes activation of factor IX. Activation of 
factor XII (Hageman factor) is produced secondary to the binding to an artificial or 
negatively charged surface. XIIa activates prekallikrein and factor XI leading to the 
formation of kallikrein and XIa.(100) Active factor IX (IXa) is produced due to 
cleavage of High-molecular-weight kininogen (HMWK).(109) 
The manifestations of intrinsic pathway deficiency vary whether in vitro or in vivo. In 
vitro, it causes prolonged partial thromboplastin time. However, it does not cause 
bleeding in vivo except for factor XI, which causes mild bleeding following trauma or 
injury.(110) It is suggested that factor XI is essential for the production of thrombin 
and down-regulation of fibrinolysis via thrombin activatable fibrinolysis inhibitor 
(TAFI). The Leiden thrombophilia study showed that increased levels of factor XI is a 
risk factor for thrombosis.(111), (112)  
Recent reports have suggested that the proteins of the intrinsic pathways are 
biologically active. Prekallikrein and HMWK are involved in the regulation of blood 
pressure and play a role in fibrinolysis. Factor XII can activate neutrophils and up-
regulate the release of cytokines from monocytes and macrophages.(113) 
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2.2.3 Tenase Complex Formation: 
This complex is formed of active factor IX (IXa), active factor VIII (VIIIa), calcium and 
phospholipids and it leads to activation of factor X to Xa. The tenase complex is the 
most important activator of factor X and it is necessary for haemostasis. Absence of 
factor VIII or factor IX produces haemorrhagic disease known as haemophilia, the 
severity of which is related to the degree of deficiency of these factors.  
 
2.2.4 Conversion of Prothrombin to Thrombin: 
The formation of active thrombin is achieved by the production of the prothrombinase 
complex. This process consists of binding active factor X to active factor V, calcium 
and phospholipid membrane. Thrombin and TF-VIIa can produce factor Va.(100) 
The tenase complex and TF-VIIa are essential in activating the vitamin-k dependent 
factor X. The tenase complex is required as the activation of factor X produced by 
TF-VIIa gets rapidly down-regulated by the effect of tissue factor pathway inhibitor 
(TFPI).   
Active factor V is required to accelerate the conversion of prothrombin to thrombin. 
This requires the binding to the phospholipid surface of activated platelets or 
monocytes.(114) α-thrombin is produced by activation of prothrombin under the 
effect of the tenase complex. This occurs through various steps, one of which 
produces the active thrombin and a by-product called Prothrombin Fragment (PF) 
1+2.(115) PF1+2 is used as a marker of thrombin production as it is more stable to 
be measured and thrombin concentration is difficult to assess. PF1+2 is considered 
an indicator of hyper-coagulability.(116) Functions of the active enzyme thrombin 
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include the conversion of fibrinogen into fibrin, activating coagulation factors V, VIII 
and XI; platelets, TAFI and protein C.(117) 
 
2.2.5 Fibrin Formation: 
This is the end stage of normal coagulation in order to seal the site of vascular injury 
and allow wound healing.  Fibrin is formed by the conversion of the soluble 
fibrinogen into an insoluble polymer. This is a multi stage process.  
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2.3 Regulation of Blood Coagulation: 
Normal blood coagulation should act locally for the appropriate period of time to 
provide enough fibrin at the site of vascular injury to ensure proper seal of the site of 
injury. If not regulated tightly, this process can cause wide spread fibrin deposition 
leading to thrombo-embolic complications.  
These regulatory mechanisms include:  
1) The coagulation system is active where the negatively charged phospholipids 
co-exist. This occurs on the surface of activated cells and platelets.  
2) TF, which is the initiator of the cascade, is abundant on the surface of 
monocytes and cells that become active in response to vascular injury.  
3) The presence of anticoagulant proteins that limit the activity of the active 
coagulation factors.  
4) Fibrinolysis.  
The anticoagulant proteins and cofactors include:  
1) TFPI which is released from endothelial cells. 
2) Anti-thrombin which binds to and neutralizes factors IXa, Xa, TF-VIIa complex 
and thrombin. Thrombin-antithrombin (TAT) complex is rapidly cleared from the 
circulation.(118) This complex is also used as a marker of hyper-coagulability 
because it is an indicator of thrombin production.(119)  
3)  Protein C pathway which is a essential in preventing thrombosis in the 
microcirculation.  
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The activation process of protein C pathway takes two steps as protein C circulates 
in an inactive form. The first step requires thrombin to produce activated protein C 
(APC). For APC to become fully active, it has to bind to protein S which is, similar to 
protein C, a vitamin K dependent plasma protein. Having no enzymatic activity, 
protein S binds to APC creating the protein S-APC complex that acts as inhibitor of 
factor Va and factor VIIIa. The full activation of the protein C pathway stops thrombin 
production by shutting down prothrombinase and tenase activity.(120) 
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2.4 Fibrinolysis: 
The fibrinolytic system controls and limit clot formation. When activated, it changes 
fibrin into fibrin fragments known as fibrin degradation products (Figure 2). The 
control of this mechanism is crucial in maintaining a haemostatic balance.  
 
          
Figure 2: Mechanism of the fibrinolytic system.  
Endothelial activation and injury causes the release of tissue plasminogen activator 
(t-PA) antigen, which converts plasminogen into the active plasmin. This active 
enzyme leads to the breakdown of fibrinogen, fibrin, and fibrin clot to fibrin 
degradation products. Plasminogen activator inhibitor (PAI) is released from the 
endothelium, hepatocytes, and platelets to inhibit t-PA. 
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2.4.1 Plasminogen and plasmin 
The breakdown of the fibrin into fibrin degradation products (FDPs) is carried out 
through the effect of the plasmin enzyme. Its precursor is the inactive plasminogen. 
Plasminogen activators lead to the formation of the active protease plasmin. The 
presence of plasminogen activators and their inhibitors is essential in controlling 
fibrinolysis.(121) 
 
2.4.2 Plasminogen activators 
tissue plasminogen activator (t-PA) is the main plasminogen activator in vivo. It is a 
serine protease that is produced by the endothelial cells. In the presence of fibrin, it 
gets bound to fibrin and activation of plasminogen is accelerated to produce plasmin. 
However, in the absence of fibrin, it is an inefficient activator of plasminogen. The 
release of t-PA at the site of vascular injury is stimulated by fibrin, thrombin attached 
to the formed clot, or by the effects of venous occlusion.(122, 123) 
 
2.4.3 Inhibitors of fibrinolysis 
α2-antiplasmin inhibits the active plasmin by forming an irreversible plasmin-
antiplasmin complex. Plasminogen activator inhibitors (PAI) is another major player 
in regulating fibrinolysis. There are four different types of PAI: PAI-1, PAI-2, PAI-3 
and protease nexin. PAI-1 is the most important in inhibiting t-PA in plasma. PAI-1 is 
mainly produced in the endothelial cells and it is usually present in excess over t-PA 
in order to prevent the premature breakdown of fibrin in the forming clot and to inhibit 
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systemic fibrinolysis. PAI-2 is produced in the placenta and is found only in the 
plasma of pregnant women. Another fibrinolysis inhibitor is TAFI, which when 
activated; it directly inhibits plasmin activity and prevents premature lysis.(124-127) 
 
2.5 Abnormal Haemostasis: 
Abnormal Haemostasis or coagulopathy occurs due to imbalance between 
coagulation and fibrinolysis. It happens as a result of excessive activation of the 
extrinsic and/or intrinsic coagulation pathways. Coagulopathy could be due to acute 
or chronic causes. TF release is the major cause of acute coagulopathy. Coagulation 
factors operate within a narrow range of temperature and pH; hence hypothermia 
and acidosis have a major impact on haemostasis. AAA may precipitate chronic 
coagulopathy.   
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2.6 The effect of AAA on haemostasis:  
AAA is characterized by chronic inflammation and the presence of mural thrombus. 
Blood flow is maintained through the mural thrombus of an aortic aneurysm, thereby 
providing an interface for exchange between the systemic circulation and 
thrombus.(128) The structure of the thrombus is highly complex with a network of 
interconnecting canaliculi which contain cellular infiltrates, including neutrophils, 
macrophages, and platelets, often in a state of de-granulation. This may lead to 
consumption of platelets and coagulation factors to such an extent that a sub-clinical 
disseminated intravascular coagulopathy (DIC) may exist.(129) Thus, the mural 
thrombus represents a biologically active entity with the ability to trap polymorph 
nuclear leukocytes, absorb circulating plasma components, and aggregate platelets 
as well as being implicated as a source of proteolysis and fibrinolytic activity thought 
to be implicit in AAA progression.(130-132) Furthermore, it has been proposed that 
the luminal part of the thrombus could play a critical role in the evolution of AAA 
through its ability to act as solid catalyst between substrates transported through the 
thrombus and proteases originating from the arterial wall. 
Several studies have examined the effects of AAA on direct and indirect biomarkers 
of thrombin generation, fibrinolysis, and platelet activity (Tables 1-3).  An elevated 
level of plasma fibrinogen is an independent risk factor for cerebrovascular events 
and myocardial infarction as well as cardiovascular mortality.(133, 134) An 
association between elevated fibrinogen and atherosclerotic peripheral arterial 
disease has been widely reported, and elevated levels of plasma fibrinogen are 
found in patients who subsequently develop peripheral arterial disease. The 
association between AAA and plasma fibrinogen levels has been extensively 
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investigated (Table 1).(18, 29, 135-141) Seven of 14 studies have reported 
significantly elevated fibrinogen levels in patients with asymptomatic AAA. 
Several studies investigated the association between AAA and fibrinolysis.(5, 18-20, 
135, 140-147) (Table 1). Some studies assessed the impact of AAA on plasma D-
dimer levels. The degradation of fibrin by plasmin ultimately results in the formation 
of D-dimer. Thus, the presence of D-dimer in the circulation represents ongoing clot 
formation and fibrinolysis. All these studies have reported elevated levels of plasma 
D-dimer in patients with AAA. On multivariate analysis, both Lee et al (143) and 
Parry et al (5) have reported an independent association between circulating D-
dimer levels and AAA. The majority of studies have reported no difference in 
circulating t-PA antigen levels in patients with or without AAA. The one exception is 
Wanhainen et al (146) who have reported elevated levels of t-PA antigen in patients 
with screen-detected AAA. Only three studies have analysed both t-PA antigen and 
PAI-1 activity levels, and all three studies have reported no significant difference 
compared to their control populations. Adam et al (34, 142) were the only group to 
report t-PA activity and PAI-1 activity levels which were comparable to the 
manufacturer’s normal reference in patients with symptomatic, non-ruptured AAA. 
Similarly, several studies have reported on the effect of AAA on the levels of TAT 
and/or PF1+2.(5, 18-20, 141, 142, 144, 145) (Table 2). Elevated levels of both TAT 
and PF1+2 have been demonstrated in men with AAA <5.5 cm in diameter. 
Wallinder et al (20) reported elevated levels of TAT, but normal levels of PF1+2. This 
may be explained by the short half-life of PF1+2 such that elevated TAT levels are 
more indicative of ongoing thrombosis, whereas PF1+2 may be more reflective of a 
single acute thrombotic event.  
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Table 1: Summary of studies investigating the association between AAA and levels of fibrinogen and biomarkers of fibrinolysis 
Study Cases Controls 
Fibrinogen 
Fibrinolysis 
D-Dimer tPA ag  PAI-1  
case Control 
P-
value Case 
control
s 
P-
value case controls 
P-
valu
e 
case controls P-value 
Adam et 
al(142) 7 0 ** 
4.85 
(1.61-
7.9) g/l 
1.5 - 
4.0 g/l 0.033 
1633 
(753-
3014) 
ng/ml 
630-
850 
ng/ml 
0.005 
1.7 (0.75-
3.2) IU/ml 
*** 
0.2-2.0 
IU/ml 
0.02
3 
6.3 
(3.2-
15.4) 
AU/ml 
<15 
AU/ml 0.005 
Adam et 
al(34) 9 0 ** 
2.80 
(1.59-
.02) g/l 
1.5 - 
4.0 g/l N/A      
0.49 (0.14-
3.2) IU/ml 
*** 
0.2-2.0 
IU/ml N/A 
8.2 
(3.2-
21.7) 
<15 
AU/ml N/A 
Al-Barjas 
et al(136) 110 110 
2.89 
(2.45-
3.4) g/l 
2.53 
(2.1-
3.07) 
g/l 
<0.01                
Blann et 
al(138) 21 42 
3.6 +/-
1.2 g/l 
3.3 +/-
0.9 0.185               
Bradbury 
et al(29) 23 0 ** 
5.16 
(2.61-
4.3) g/l 
1.5-4.0 
g/l n/s               
Fowkes et 
al(135) 89 98 
3.5 
(2.9-
4.1) g/l 
3.1 
(2.7-
3.6) g/l 
0.02 
441.5 
(198.8-
771.0) 
ng/ml 
93.0 
(57.8-
158.8) 
ng/ml 
<0.00
1 
7.9 (6.0-
11.1) ng/ml 
8.6 (6.8-
11.5) 
ng/ml 
0.64      
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Holmberg 
et al(137) 23 o ** 
3.6 
(1.9-
6.3) g/l 
2.0-3.6 
g/l n/s               
Holmberg 
et al(19) 23 20    
571 
(60-
1515)  
µg/L 
32 (10-
536)  
µg/L 
<0.01 
10.2 (4.9-
24.2)  
µg/ml 
9.4 (2.9-
19.0)  
µg/ml 
>0.0
5 
3.5 
(2.0-
33.1) 
IU/ml 
4.7 (2.0-
30.9) 
IU/ml 
>0.05 
Hosaka et 
al(141) 49 o ** 
336 +/- 
85 
mg/dl 
160-
350 
mg/dl 
N/A 
8.5 +/- 
6.7 
µg/ml 
<1.0 
µg/ml N/A          
Ihara et 
al(145) 22 26     
732.6 
+/- 
858.6 
ng/ml 
125.7 
+/- 46.1 
ng/ml 
<0.00
01          
Jelenska 
et al(144) 20 22 
4.2 +/- 
79 
mg/dl 
313+/- 
55 
mg/dl 
<0.00
1 
778 +/-
311 
ng/ml 
362 +/- 
242 
ng/ml 
<0.00
1         
Kolbel et 
al(148) 78 121                 
Lee et 
al(143) 40 200 
3.05 
(2.61-
3.57) 
g.l 
2.62 
(2.21-
3.08) 
g/l 
<0.00
1 
142 
(84-
209.5) 
ng/ml 
83 
(67.5-
129) 
ng/ml 
<0.00
1 
8.5 (7-10.5) 
ng/ml 
7.9 (5.8-
10.1) 
ng/ml 
NS     
Milne et 
al(149) 105 32                 
Parry et 
al(5) 
75 
male
s 
90 
2.92 
(0.76) 
g/l 
2.59 
(0.65) 
g/l 
0.019 
346.7 
(288.5-
427.5) 
ng/ml 
120.2 
(106.9-
134.2) 
ng/ml 
<0.00
1 
9.12 (8.03-
10.50) 
ng/ml 
8.80 
(8.14-
9.51) 
ng/ml 
0.71
9 
17.9 
(15.4-
20.4) 
ng/ml 
16.2 
(14.4-
17.9) 
ng/ml 
0.619 
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Shindo et 
al(140) 43 o ** 
300.2 
+/- 
15.5 
mg/dl 
150-
330 
mg/dl 
N/A 
10.6 
+/- 2.0 
µg/ml 
<0.8 
µg/ml N/A          
Sofi et 
al(147) 438 438             
28.6 
+/- 
21.6 
mg/dl 
17.8 +/- 
12.6 
mg/dl 
<0.00
01 
Singh et 
al(139) 
263 
♂ 2699 ♂  
3.72 
(0.91) 
mmol/l 
3.32 
(0.88) 
mmol/l 
<0.00
1               
74 ♀ 3350 ♀  
3.77 
(0.68) 
mmol/l 
3.43 
(0.80) 
mmol/l 
<0.00
1               
Wallinder 
et al(20) 40 41    
625 
(460-
1437) 
ng/ml 
86 (38-
176) 
ng/ml 
<0.00
1 
10.5 (8.6 -
14.8) ng/ml 
11.1 (8.5-
15.2)ng/
ml 
>0.0
5 
4.0 
(1.9-
8.7) 
IU/ml 
2.7 (1.9-
7.9) 
IU/ml 
>0.05 
Wanhaine
n et 
al(146) 
42 100         13.6 +/- 4.7 µg/ml 
11.4 +/- 
4.3 µg/ml 
0.01
6      
Yamazum
i et al(18) 36 25 
326 +/- 
77 
mg/dl 
298 +/- 
63 
mg/dl 
0.21 
7.7 +/- 
6.7 
µg/ml 
1.0 +/- 
1.2 
µg/ml 
<0.01             
** Manufacturer’s range 
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Table 2: Summary of studies investigating the association between AAA and biomarkers of thrombin generation 
Study Cases 
Contro
ls 
Thrombin Generation 
TAT F1+2 FDP APC-PCI 
Case controls 
P-
valu
e 
Case Controls P-value case controls P-value case controls 
P-
value 
Adam et 
al(142) 7 0**    
2.1(1.1-5.2) 
nmol/l 
0.4-1.1 
nmol/l 0.001             
Adam et 
al(34) 9 0** 
21.6 (6.6-
180.4) 
µg/L 
1.0-4.0 
µg/L N/A 
2.2 (0.7-7.1) 
nmol/l 
0.4-1.1 
nmol/l N/A           
Holmberg 
et al(19) 23 20 
11.5 (2.6-
30.3) 
µg/L 
2.6 (2.0-
5.6)  µg/L 
<0.0
1 
2.2 (0.9-4.6) 
nM 
1.2 (0.5-
3.1) nM >0.05           
Hosaka et 
al(141) 49 0** 
11.5 +/- 11.3 
ng/ml 
<3.5 
ng/ml N/A                
Ihara et 
al(145) 22 26 
16.4 +/- 16/9 
ng/ml 
2.6 +/- 1.3 
ng/ml 
<0.0
001                
Jelenska et 
al(144) 20 22    
1.17 +/- 
0.36nM 
0.99 +/- 
0.28 nM <0.001           
Kolbel et 
al(148) 78 121             
0.45 (0.24-
1.47) µg/l  
0.15 
(0.10-
0.23) 
µg/l 
<0.000
1 
 
Parry et 
al(5) 
 
 
75 
male
s 
90 
4.57 (2.68-
8.7) 
ng/ml 
1.89 
(1.48-
2.49) 
ng/ml 
<0.0
01 
1.33 (0.98-
1.79) ng/ml 
0.82 
(0.75-
0.90) 
ng/ml 
0.004           
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Shindo et 
al(140) 43 0**        
718.6 
+/- 
138.2 
ng/ml 
<100 
ng/ml N/A      
Wallinder 
et al(20) 40 41 
6.0 (3.8-9.1) 
µg/ml 
2.9 (2.1-
3.9) 
µg/ml 
<0.0
01 
0.8 (0.6-1.1) 
nmol/l 
0.8 (0.6-
1.0) 
nmol/l 
>0.05           
Yamazumi 
et al(18) 36 25 
17.4 +/- 13.6 
ng/ml 
3.8 +/- 2.2 
ng/ml 
<0.0
1       
11.6 
+/- 
12.0 
µg/ml 
3.6 +/- 
2.0 
µg/ml 
 <0.01       
** Manufacturer’s range 
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Table 3: Summary of studies investigating the association between AAA and vWF, platelet count, and sP-selec 
Study Cases Controls vWF Platelet count sP-selec 
case Controls P-value case controls P-value case controls P-value 
Adam et 
al(142) 7 0 **      
183 (75-
292) 
x109/l 
150-350 
x109/l <0.05      
Blann et 
al(138) 21 42 
123 +/-
37 IU/dl 
113 +/- 
32 IU/dl <0.001      
325 
(155-
4253) 
ng/ml 
202 (80-
440) 
ng/ml 
<0.001 
Bradbury et 
al(29) 23 0 **      
204 
(140-
293) 
x109/l 
150-350 
x109/l >0.05      
Fowkes et 
al(135) 89 98 
122.5 
(98.0-
150.2) 
IU/dl 
123.0 
(101.0-
152.0) 
IU/dl 
0.55           
Holmberg et 
al(19) 23 20                
Ihara et 
al(145) 22 26                
Milne et 
al(149) 105 32      
215+/- 
47.5 x 
109/l  
269+/-
57 x 
109/l 
<0.0001      
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Shindo et 
al(140) 43 0 **      
17.9 +/- 
5.7 x 
103/mm3 
15.7-
34.2 x 
103/mm3 
N/A      
Wallinder et 
al(20) 40 41 
154 
(138-
176) % 
150 
(125-
165) % 
>0.05 
216 
(176-
242) 
x109/l 
207 
(177-
238) 
x109/l 
>0.05      
Yamazumi et 
al(18) 36 25       
19.6 +/- 
5.4 x 
104/µL 
23.7 +/- 
6.1 x 
104/µL 
 <0.05       
** Manufacturer’s range 
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2.7 Association between AAA morphology and haemostasis:  
Seven studies have reported on the correlation between AAA maximum diameter, 
thrombus volume, and markers of haemostasis (18, 20, 22, 136, 140, 141, 150, 151) 
(Table 4). Some authors have demonstrated a correlation between AAA size and 
total volume/maximum thrombus thickness and the changes in thrombin generation 
and fibrinolysis. By contrast, Kölbel et al (148) have failed to show a correlation 
between APC-PCI levels and thrombus volume or thrombus intra-luminal surface 
area. Yamazumi et al (18) have reported a correlation between AAA tortuosity and 
markers of thrombosis which may represent the association between blood flow 
velocity changes, particularly turbulent flow, and red blood cell (RBC) activation. 
Shindo et al (140) have reported a correlation between RBC counts and the AAA 
lumen volume. Activated RBCs release adenosine di-phosphate resulting in platelet 
aggregation and activation.(152) The consumptive coagulopathy, resulting from the 
thrombus mass and the abnormal flow field in a tortuous lumen may both contribute 
to the haemostatic derangement in patients with AAA. 
 
 
 
34	
	
Table 4: Summary of studies investigating the association between AAA morphology and biomarkers of haemostasis 
Biomarker Study Maximum diameter of AAA 
Worst angle along 
length of AAA 
Max thickness of intra-
luminal AAA thrombus 
Total Intra-luminal AAA 
thrombus volume 
APC-PCI Kolbel et al(148) r=0.22, p=0.001     r=0.123, p=0.142 
D-Dimer 
Shindo et al(140) r=0.208, p=NS     r=0.208, p=NS 
Wallinder et al(20) r=0.427, p<0.001       
Yamazumi et al(18) r=0.644, p=0.0001 r=-0.411, p=0.009 r=0.650, p=0.0001   
F-TFPI Yamazumi et al(18) r=0.408, p=0.016 r=-0.583, p=0.0006     
FDP 
Shindo et al(140) r=0.208, p=NS     r=0.171, p=NS 
Yamazumi et al(18) r=0.561, p=0.0009   r=0.513, p=0.0024   
Fibrinogen Al-Barjas et al(136) r-0.323, p<0.01     r=0.323, p<0.05 
FM-FC Hosaka et al(141) r=0.128, p=0.381   r=0.233, p=0.125   
PAI-ag Aho et al(22)       r=0.51, p<0.007 
PIC Yamazumi et al(18) r=0.413, p=0.0146   r=0.484, p=0.042   
TAT 
Wallinder et al(20) r=0.28, p=0.018       
Yamazumi et al(18) r=0.566, p=0.001 r=-0.366, p=0.0305 r=0.677, p=<0.0001   
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2.8 The effect of open surgical repair on biomarkers of haemostasis: 
Major surgery is known to produce a pro-thrombotic derangement with raised levels 
of factor VIII, fibrinogen, TAT, vWF, platelet hyperactivity, and evidence of deranged 
fibrinolysis.(23-28) Studies reporting the effect of open surgical AAA repair on 
haemostasis are summarized in (Table 5). Aho et al (22) have reported significantly 
elevated levels of PF1+2 at 72 hours postoperatively compared to pre-operative 
levels. There was a non-significant trend toward elevated levels of TAT, D-dimer, t-
PA antigen, and PAI antigen within the first 72 hours postoperatively. These 
biomarkers returned to pre-operative levels by 3 months after the operation, but 
remained elevated when compared to healthy individuals suggestive of ongoing up-
regulation of thrombin generation and fibrinolysis. Yamazumi et al (18) have reported 
significantly lower levels of TAT and D-dimer at 3 months following open repair when 
compared to pre-operative levels. Holmberg et al (153) have reported similar findings 
with elevated peri-operative levels of TAT and PF1+2 which returned to pre-
operative levels by 1-week postoperatively, but remaining elevated compared to age-
matched controls (AMC). In a separate study, the same group has reported that 
open surgical repair reduced the pre-operative thrombotic derangement in the long-
term with a reduction in TAT and D-dimer levels at a median follow-up of 26 months 
(19). However, the values remained slightly higher than the normal healthy reference 
ranges suggesting ongoing haemostatic derangement despite thrombus volume 
reduction. 
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Table 5: Summary of studies investigating the effects of open surgery on biomarkers of haemostasis 
Biomarker Study Controls (units) 
Pre-
operative  24 hours 72 hours 1 week 3 months >12 months  
Value Value p-value Value p-value Value p-value Value p-value Value p-value 
D-dimer 
Holmberg 
et al(19) 
32 (10-
536)  µg/L 
511 (60-
1275) 
                
39 (23-
326)  
<0.05 
Yamazumi 
et al(18) 
1.0 +/- 1.2 
µg/ml 
7.7+/-6.7              
4.6+/-
3.5  
<0.01     
PF1+2 
Aho et 
al(22) 
0.4-1.1 
nmol/ml 
1.6+/-0.6  
1.5+/-
1.2  
NS 
2.0+/-
0.9  
<0.05 
1.9+/-
0.8  
NS 
1.4+/-
0.6  
NS     
Holmberg 
et al(153) 
1.2 (0.5-
3.1) nM 
2.2 (0.9-4.6)  
        
2.7 (1.5-
5.7)  
NS 
        
Holmberg 
et al(19) 
1.2 (0.5-
3.1) nM 
1.4 (0.0-4.6)                  
1.2 (0.8-
3.0)  ** 
NS 
FDP Yamazumi et al(18) 
3.6 +/- 2.0 
µg/ml 
11.6 +/- 
12.0              
7.6+/-
4.6  0.17     
Fibrinogen 
Aho et 
al(22) 
1.7-4              
g/l * 
3.9+/-0.8 
3.5+/-
0.7 
NS 
7.1+/-
2.0 
<0.05 
5.9+/-
1.3 
NS 
3.8+/-
0.4   
NS     
Holmberg 
et al(137) 
2.0-3.6 g/l 
* 
3.6 (1.9-6.3)  
        
5.6 (3.3-
8.4)  
<0.001 
        
Yamazumi 
et al(18) 
298 +/- 63 
mg/dl 
326 +/- 77              
331+/-
55  
0.75     
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PAI Ag 
Aho et 
al(22) 
4-43          
ng/ml 
18.8+/-6.0  
32.4+/-
13.3  
<0.05 
27.9+/-
6.2  
NS 
25.9+/-
10.7 
NS 
15.4+/-
6.0  
NS     
Holmberg 
et al(19) 
4.7 (2.0-
30.9) 
IU/ml 
5.6 (2.0-
29.3) 
                
9.9 (2.0-
54.5)  
NS 
Platelet 
Count 
Bradbury 
et al(29) 
150-350   
x109/l * 
292 (179-
51)         x 
109/L 
187 
(103-
364) 
x109/l 
<0.001                 
Yamazumi 
et al(18) 
23.7 +/- 
6.1      x 
104/µL 
19.6 +/- 5.4 
x 104             
21.2+/-
5.0 x 104 <0.05     
TAT 
Holmberg 
et al(153) 
 
Holmberg 
et al(19) 
2.6 (2.0-
5.6)  µg/L 
11.5 (2.6-
30.3)   
        
 11.8 
(4.4+/-
31.3) 
NS         
2.6 (2.0-
5.6)  µg/L 
11.5 (2.6-
26.1)  
                
3.8 (2.7-
16.2)** 
<0.05 
Yamazumi 
et al(18) 
3.8+/-2.2 
ng/ml 
17.4 +/-13.6              
10.4+/-
4.5  
<0.01     
tPA Ag 
Aho et 
al(22) 
 
Holmberg 
et al(19) 
1-20          
ng/ml 9.7+/-2.6  
14.3+/-
4.9  <0.05 
13.6+/-
4.3  NS 
11.2+/-
4.6  NS 
9.1+/-
2.8  NS     
9.4 (2.9-
19.0)  
µg/ml 
10.3 (7.6-
15.3)                 
12.5(6.6-
14.9) NS 
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2.9 The effect of EVAR on biomarkers of haemostasis:  
Five studies have reported the effects of EVAR on haemostasis (22, 43, 154-156) 
(Table 6). Serino et al (156) have reported the short-term effects of EVAR on 
circulating D-dimer levels in nine patients assessed pre-operatively and day 4 
postoperatively. D-dimer levels were elevated in seven patients and decreased in 
two patients. The median level for the entire patient cohort did not demonstrate a 
statistically significant difference. This lack of statistical significance may represent a 
type II error. Monaco et al (154) have reported a significant decrease in levels of 
platelets, fibrinogen, plasminogen, and prothrombin activity in patients undergoing 
EVAR during the first 10 days after the operation. This was associated with 
increased D-dimer and fibrin degradation product (FDP) levels suggestive of 
coagulation factor/platelet consumption coupled with hyper-fibrinolysis during the 
peri-operative period in patients undergoing EVAR. By 1-month post-EVAR, all 
biomarkers returned to pre-operative levels with the exception of fibrinogen, which 
peaked at 1-month and remained significantly elevated at 6-months post-operatively. 
Three studies have compared open surgical repair with EVAR on haemostasis. 
Engleberger et al (43) have reported elevated levels of markers of thrombin activity 
(fibrinopeptide A and FM), thrombin formation (TAT) and fibrinolysis (D-dimer) in 
both groups during the peri-operative period with return to pre-operative values by 
post-operative day 5. During this period, inter group comparison revealed 
significantly elevated levels of thrombin activity and formation in the EVAR group. 
Aho et al (22) have reported similar changes in the peri-operative period with 
elevated levels of markers for thrombin formation (TAT, PF1+2) and fibrinolysis (D-
dimer, t-PA antigen). The post-operative increase in TAT levels was found to be 
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earlier and more pronounced in the EVAR group compared to the open group (day 1 
vs day 3). All markers of haemostasis returned to pre-operative levels by 1 week 
post-operatively with the exception of D-dimer. D-dimer increased in both groups 
after surgery and remained above normal values for 3 months. However, compared 
to pre-operative levels, only the EVAR group demonstrated a significant increase in 
D-dimer at 3 months. Fibrinogen decreased in both groups during the first 24 hours 
post-operatively, but thereafter increased such that at 72 hours it was significantly 
elevated compared to pre-operative values, but no inter group difference was found. 
Odegård et al (155) have reported similar findings in the peri-operative period for 
both EVAR and open repair. These changes in fibrinogen can be explained by 
consumption and/or depletion due to operative blood loss during the first 24 hours, 
followed by an increase in levels due to ongoing inflammation associated with the 
endoprosthesis/graft as indicated by elevated levels of C-reactive protein and 
interleukin (IL)-6.  
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Table 6: Summary of studies investigating the effects of EVAR on biomarkers of haemostasis and comparing them to open repair 
Biomarker Study Type of 
repair 
Controls 
(units) 
Pre-op 
Value  
  24 hours 72 hours 
Inter-
group P-
value 
Value Intra-group 
p-value 
Inter-
group 
P-value 
Value Intra-group 
P-value 
Inter-group 
P-value 
D-dimer Monaco et 
al(154) 
Endo <450ng/ml* 278+/-93.3   428.44+/-
147.3 
<0.01         
PF1+2 Aho et al(22) Open 0.4-1.1  
nmol/ml  * 
1.6+/-0.6  NS 1.5+/-1.2  NS NS 2.0+/-0.9  <0.05 NS 
Endo 1.4+/-0.4 2.0+/-1.0 NS 2.3+/-0.9 <0.05 
FDP Monaco et 
al(154) 
Endo <100ng/ml 
* 
6.3 +/- 1.3   11.2 +/- 3.8 <0.01         
Fibrinogen Aho et al(22) Open 1.7-4              
g/l * 
3.9+/-0.8 NS 3.5+/-0.7 NS NS 7.1+/-2.0 <0.05 NS 
Endo 3.7+/-0.6 3.5+/-0.8 NS 6.1+/-1.6 <0.05 
Odegard et 
al(155) 
Open N/A g/l         
Endo         
Monaco et 
al(154) 
Endo 160-350    
mg/dl * 
309.6+/-
50.6 
  159.4+/-
44.9 
<0.01         
PAI Ag Aho et al(22) Open 4-43          
ng/ml * 
18.8+/-6.0  NS 32.4+/-13.3  <0.05 NS 27.9+/-6.2  NS NS 
Endo 16.5+/-6.4 24.5+/-8.5 <0.05 21.3+/-8.2 NS 
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Platelet 
Count 
Englberger 
et al(43) 
Open N/a x 109/l 232+/-52 0.82 143+/-52  0.41       
Endo 226+/-46 165+/-56     
Monaco et 
al(154) 
Endo 130-340 
x103/dl * 
233.2+/-
52.9 
  190.9+/-
48.4 
<0.05         
tPA Ag Aho et al(22) Open 1-20          
ng/ml * 
9.7+/-2.6  NS 14.3+/-4.9  <0.05 NS 13.6+/-4.3  NS NS 
Endo 8.5+/-3.1 11.4+/-4.1 <0.05 9.9+/-4.3 NS 
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Table	6	(continue):	
5-7 days Post-op 3 months 6 months 
Value Intra-group 
p-value 
Inter-group 
P-value 
Value Intra-group 
p-value 
Inter-group 
P-value 
value Intra-group 
P-value 
Inter-group 
P-value 
420.5+/-149.8 <0.05         265.9+/-86.9 >0.05   
1.9+/-0.8  NS NS 1.4+/-0.6  NS         
2.0+/-0.7 NS 1.7+/-0.6 NS         
12.0+/-3.4 <0.01         6.0 +/- 1.0 >0.05   
5.9+/-1.3 NS NS 3.8+/-0.4   NS NS       
6.1+/-2.1 NS 3.6+/-0.7 NS     
5.8 (4.9-6.9) P<0.001 NS        
5.8 (5.0-6.7) p<0.001        
187.3+/-44.7 <0.01         348.8+/-79.7 <0.01   
25.9+/-10.7 NS NS 15.4+/-6.0  NS NS       
25.3+/-8.0 NS NS 18.6+/-6.4 NS       
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229+/-75  0.98             
229+/-74         
170.6+/-34.7 <0.001         237.8+/-60.3 >0.05   
11.2+/-4.6  NS NS 9.1+/-2.8  NS NS       
10.3+/-4.9 NS 8.7+/-3.2 NS       
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Chapter 3 
General Background 3 
3.1 Effect of EVAR on Renal function: 
The effect of EVAR on renal function remains uncertain. Early reports showed a 
significant increase in sCr and reduction in creatinine clearance (CrC) following 
EVAR.(157-159) The incidence of renal impairment following EVAR has been 
reported to be 6-29% depending on the presence of pre-operative renal 
impairment.(160, 161) Other studies have failed to demonstrate a significant change 
in renal function following EVAR.(162, 163) Deterioration in renal function following 
fenestrated EVAR has been reported to be as high as 10-30% (16% in those without 
renal dysfunction and 39% for patients with pre-operative renal dysfunction).(91, 98, 
164, 165) 
In clinical practice, sCr is the most commonly used marker to assess renal function 
(RF). However, sCr appears to be a rather unreliable marker of RF because sCr 
concentrations are affected by tubular secretion, age, sex, muscle mass, physical 
activity, and diet, and therefore it does not have a direct relationship with the 
glomerular filtration rate (GFR).(166) The Cockcroft-Gault (167) and the Modification 
of Diet in Renal Disease (MDRD) (168) equations, both based on sCr, are being 
used increasingly because they overcome, at least in part, some of the limitations of 
sCr measurements. Both equations are currently recommended for the estimation of 
GFR, which is an established method for detection and classification of Chronic 
kidney disease (CKD) in clinical practice.(169) However, these creatinine-based 
equations, which have been validated in patients with CKD, have several limitations, 
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particularly among CKD patients with multiple co-morbidities, elderly individuals, 
obese patients, and patients with only mild impairment of RF.(170-172) 
sCr is considered relatively specific, but not very sensitive since its levels 
significantly increase when more than 50% of the GFR is reduced.(173) Its 
concentration may be significantly influenced by several extra-renal factors (muscle 
mass, changes in tubular secretion, dietary intake). Especially in elderly female 
patients with reduced muscle mass, measurement of sCr may grossly underestimate 
the reduction in the GFR. Finally, numerous drugs and endogenous substances also 
interfere with the measurement of sCr, leading to falsely high or low values. 
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3.2 Cystatin C: 
Cystatin C (cyst C) is an endogenous marker of renal function that is believed to be 
more sensitive in detecting mild to moderate reduction in GFR. It is produced by all 
nucleated cells and it is related to the cysteine proteinase inhibitors. Cyst C is filtered 
freely across the glomerular membrane and is metabolized in the proximal tubules.  
Several studies have suggested that its level is not affected by age, sex, or muscle 
mass and it is more accurate than sCr for detection of early renal impairment.(174) 
In the Chronic Kidney Disease Epidemiology (CKD-Epi) Study, although both sCr 
and cyst C were associated with demographic factors independent of direct 
measures of GFR, this was to a larger extent for sCr.(175) Increased weight and 
height, current smoking, higher C-reactive protein (CRP) levels, hyperthyroidism and 
glucocorticoid use have also been associated with higher cyst C levels (176-178) 
and more recent studies have noted associations with obesity and waist 
circumference, (179, 180) as well as secretion of cyst C by adiposities.(181) In the 
MDRD Study, cyst C was however highly correlated with GFR suggesting that kidney 
function is the primary determinant of cyst C in CKD.(182) 
Multiple studies have compared cyst C and sCr as predictors of GFR. Most studies 
have found cyst C to be a better predictor, although others have found no difference. 
However, there is still some evidence that it has more clinical importance than sCr 
alone or Estimated GFR (eGFR). Cyst C may be used to detect and diagnose acute 
kidney injury (AKI) in critically ill patients one or two days earlier when compared to 
sCr measurements. Serum Cyst C is an indicator of impaired glomerular 
filtration(183), whereas, the urinary cyst C to creatinine ratio is a good indicator of 
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renal tubular dysfunction. Moreover, urinary cyst C has been used in cases of AKI to 
anticipate the requirement for renal replacement therapy earlier than urinary 
creatinine. 
 
3.2.1 Cystatin C as a measure of GFR 
Investigators from CKD-EPI developed three GFR estimating equations for cyst C: 
using cyst C alone, cyst C with demographic coefficients, and cyst C with sCr and 
demographic coefficients. Cyst C alone provided GFR estimates that were nearly as 
accurate as the MDRD equation; however, an equation including cyst C, sCr and 
demographic coefficients provided the most accurate estimates. Among patients with 
known CKD, defined as creatinine-based eGFR< 60 ml/min 1.73m2, cyst C offered 
only a moderate gain over sCr for approximating GFR;(175) however, in patients 
with early kidney disease, for example diabetics, changes in GFR over time have a 
stronger correlation with cyst C than sCr.(184, 185) Cyst C may also have 
advantages over sCr in conditions of decreased mass including older adults, those 
with chronic diseases (such as heart failure, cirrhosis, AIDS) and those without 
established CKD; however since studies in these populations lack direct GFR 
measurements, validated equations incorporating cyst C have not been 
developed.(186) 
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3.2.2 Association between cyst C and cardiovascular disease 
High concentrations of circulating cyst C have been consistently and strongly 
associated with cardiovascular outcomes. Furthermore, Cyst C is superior over other 
renal markers through providing prognostic information in some cardiovascular 
conditions. In one study, the prognostic value of serum cyst C has been investigated 
in cases of acute Heart Failure (HF) in comparison with other renal markers.(187) 
The mortality rate in acute HF has been found to be significantly high with high cyst 
C. Moreover, the mortality rate in patients with high cyst C was significantly higher at 
12 months when compared to patients with normal sCr levels: 40.4% vs 12.6%. 
Manzano-Fernandez et al produced similar findings in their study.(188) Another 
study showed that cyst C has been used to predict cardiovascular mortality in elderly 
patients with chronic HF.(189) 
Cyst C has been shown to be a risk factor for HF and cardiovascular disease 
mortality in the general population.(190) Higher levels of cyst C have been 
associated with left ventricular (LV) hypertrophy.(191) Being an inhibitor of elastolytic 
proteases, cyst C was found to be involved in atherosclerosis. The increased plasma 
concentrations of cystatin C may indicate an attempt to counter-balance the 
potentially damaging increased elastolytic activity.(192) Several studies have 
reported increased risk of death, myocardial infarction (MI), or HF in patients with 
cardiovascular disease and high levels of cyst C.(193, 194) 
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3.2.3 Association between cyst C and AAA 
AAA involved extensive extracellular matrix degradation and remodelling of the aortic 
wall. Several matrix metallo-proteases and serine proteases have been reported to 
be involved.(195, 196) Two elastolytic cysteine proteases, cathepsin S and K, have 
been isolated and are over-expressed in atherosclerotic lesion compared to normal 
arteries.(197) Macrophages and smooth muscle cells are present in the aneurysm 
wall and are capable of releasing cathepsins.(198) Cyst C is the most available 
extra-cellular inhibitor of the cysteine proteases. In one study, cyst C correlated 
negatively with AAA size and annual expansion rate. Cyst C level was found to be 
predictor of size expansion to >5 cm at the time of AAA repair. They concluded that 
cyst C deficiency is associated with increase aneurysm size and expansion 
rate.(199) 
In summary, AAA is a leading cause of death worldwide, with strong association with 
atherosclerotic cardiovascular disease. There is a strong association between 
deranged haemostatic markers and cardiovascular morbidity. AAA is characterized 
by chronic inflammation and the presence of mural thrombus. Blood flow is 
maintained through the mural thrombus providing an interface for exchange between 
the systemic circulation and thrombus. This may lead to consumption of platelets 
and coagulation factors. 
Major surgery results in a peri-operative pro-thrombotic diathesis as well as 
deranged fibrinolysis and platelet hyperactivity. However, the effect of open and 
endovascular aneurysm repair on coagulation, fibrinolysis and renal function remains 
uncertain. Several studies have reported conflicting results.  
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Chapter 4 
Aims 
Due to the uncertainty of the effect of OAR and EVAR on haemostasis and renal 
function, we aim to explore, investigate and answer the following key points: 
1. To determine the difference in coagulation and fibrinolysis between patients 
with asymptomatic AAA and AMC.  
2. To determine the changes that occur in the coagulation and fibrinolytic 
systems in the peri-operative period and up to 12 months following 
endovascular aneurysm repair. 
3. To investigate the medium term effects of EVAR and OAR on coagulation and 
fibrinolysis and compare these changes between the two groups of patients.  
4. To compare the utility of Cyst C, sCr, and eGFR as markers of renal function 
following standard and fenestrated EVAR. 
5. To look into the impact of EVAR and F-EVAR on renal function using Cyst C, 
sCr and eGFR and compare the changes in these markers.  
6. To determine the sensitivity of Cyst C in detecting minor renal damage 
following EVAR.  
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Chapter 5 
Study Design 
5.1 Ethics: 
Ethical approval was obtained from Birmingham East, North and Solihull and 
Birmingham South Research Ethics committees.   
 
5.2 Patients: Patients were included in the research unless they have one or more 
of the exclusion criteria.  
5.2.1 Exclusion criteria  
1. Recent (vascular and non-vascular) surgical or endovascular procedure within 
3 months previous to recruitment.  
2.  Presence of hereditary or acquired conditions that alter coagulation, 
fibrinolysis or platelet function. 
3. Patients presenting with symptomatic AAA.  
4. Patients on anticoagulation therapy with vitamin K antagonist.  
5. Patients unable or unwilling to give fully informed consent. 
5.2.2 Patients  
5.2.2.1 Group 1: 
Patients presenting to the Vascular Surgery Units of the Heart of England NHS 
Foundation Trust and University Hospital Birmingham NHS Trust and underwent 
elective endovascular AAA repair. Patients who were willing and able to give fully 
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informed written consent were prospectively recruited. It was estimated that a 
minimum of 25 (sample size + an estimated 30% drop-out rate) patients will be 
recruited in a 12-month period and these patients will be followed-up for a minimum 
of 12 months. 
Recruitment started in July 2008 and continued till April 2009. The study was 
discussed with patients who potentially fulfilled the inclusion and exclusion criteria 
and they were given a copy of the patient information sheet by their responsible 
consultant or one of the team. Patients were then approached by a member of the 
research team after they had sufficient time (at least 24 hours) to study the patient 
information sheet. The member of the research team discussed the research project, 
determined if the patients met the inclusion or exclusion criteria and invited the 
patient to be included in the study. Patients who agreed to participate in the study 
were asked to give fully informed written consent. 
During the recruitment period, 35 patients were approached for recruitment before 
they had elective EVAR. Two patients refused to participate in the study, and two 
were on anticoagulation and were excluded. The remaining 31 patients were 
recruited. One patient withdrew from the study on the first post-operative day and 
one died of massive myocardial infarction 3 months after the operation.  
Twenty-nine patients (27 men and 2 females) completed the twelve months follow up 
period as per protocol of the research. The mean age of these patients was 77 years 
(range, 55-89 years). The mean diameter of the AAA sac was 6.9 cm (range, 5.5-10 
cm). 19 patients underwent standard EVAR for infra-renal AAA and 10 patients had 
F-EVAR for juxta or supra-renal AAA. General anaesthesia was used in 12 patients, 
whereas 17 patients had the procedure under epidural anaesthesia. All patients 
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received bolus injection of intravenous heparin (3000 units for standard and 5000 
units for F-EVAR) prior to inserting the stent graft. Twenty-two patients were taking 
antiplatelet (aspirin 75 mg daily), 14 were being treated for hypertension, 16 had a 
history of ischemic heart disease, 14 had renal impairment, 3 were diabetics, 22 had 
hypercholesterolaemia, 3 had peripheral vascular disease (PVD) and 5 had chronic 
obstructive airway disease (COPD). (Table 7)  
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Table 7: Group 1 patients’ demographics and significance of co-variables 
 
 
 Significance 
Mean Age (range) 
 
76.9 yrs (55.2-88.5) N/A 
>75 yrs (%) 
 
<75 yrs (%) 
18 (62.1%) 
 
11 (3.9%) 
* on pre-operative TAT & 
t-PA antigen  
Sex (M:F) 
 
27:2 (93.1%:6.9%) N/A 
HT (%) 
 
14 (48.3%) * on hsCRP at one mth 
IHD (%) 
 
16 (55.2%)  * on sP-selec pre-op & 24 
hrs 
CKD (%) 
 
14 (48.3%) No significance  
Mean aneurysm size 
(range) 
6.9 cm (5.5-10) N/A 
Aneurysm Anatomy (%) 
- Infra-renal 
 
 
19 (65.5%) 
 
 
* on pre-op hsCRP 
EVAR (%) 
- Standard 
- Fenestrated  
 
19 (65.5%) 
10 (34.5%) 
* on hsCRP at 1,6 & 12 
mths 
Anaesthesia  
- General 
- Epidural  
 
12 
17 
N/A 
Make of Stent (%) 
- Zenith  
- Excluder  
 
23 
6 
* on TAT & hsCRP at 1, 6 
& 12 mths and t-PA 
antigen at 1 mth 
Patients on anti-platelets 
(aspirin) (%) 
22 (75.9%) * on sP-selec pre-op & 24 
hrs 
HT: hypertension; IHD: ischaemic heart disease; *: significant (p,0.05); mths: months 
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5.2.2.2 Group 2:  
Eleven patients (nine men and two women) were recruited after they had OAR. The 
mean age at the time of surgery was 70.2 years (range 55-83). Median time between 
OAR and collecting the blood samples was 16 months post-operatively (range 7-21 
months). They were all unsuitable to have EVAR at the time of the initial aneurysm 
repair due to anatomical variations of the aneurysm. These patients could have been 
suitable for FEVAR, however, this option was not available at the time of the 
operation. (Table 8) 
Table 8: Reason for unsuitability for EVAR among the OAR group 
Patient’s	
number	
Reason		
	
1	
	
Angulated	(65	degrees)	short	neck	
2	
	
Conical	neck	with	large	accessory	renal	
artery	arising	of	the	lower	part	of	the	
neck	
3	
	
Calcified	and	stenosed	iliac	arteries	
4	
	
Angulated	(90	degrees)	short	neck	
5	
	
Angulated	(70	degrees)	conical	neck	
6	
	
Irregular	neck	containing	thrombus	
7	
	
Juxta-renal	AAA	
8	
	
Young	age	
9	
	
Juxta-renal	AAA	
10	
	
Severe	conical	neck	
11	
	
Angulated	(80	degrees)	neck		
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5.2.2.3 Group 3:  
Eight AMC without AAA (four men and four women), as documented by CT scan, 
were recruited. The mean age was 73.1 years (range 65-90). The CT scans were 
performed for various reasons. Five patients had CT scan as 2-years post-operative 
follow up following colon resection for colon cancer and three patients had the scan 
for non-specific abdominal pain. 
 
Table	9:	Demographics	of	patients	in	the	three	groups	
HT;	hypertension,	IHD;	ischemic	heart	disease,	CVA;	cerebral-vascular	accidents,	CKD;	chronic	kidney	
disease,	NS;	not	significant		
	
	
AMC	group	
(n=8)	
EVAR	group	
(n=29)	
OAR	group	
(n=11)	
P-value		
(Fisher’s	Exact	
test)	
Age	(mean	±	SD)	 73.1	±	8	 76.9	±	7.4	 70.2	±	8.7	 0.024	
Sex	(%	men)	 4	(50)	 27	(93.1)	 9	(81.8)	 0.014	
HT	(%)	 3	(37.5)	 14	(48.3)	 6	(54.5)	 NS	
IHD	(%)	 1	(12.5)	 16	(55.2)	 5	(45.5)	 NS	
CVA	(%)	 0	 3	(10.3)	 1	(9.1)	 NS	
CKD	(%)	 1	(12.5)	 14	(48.3)	 1	(9.1)	 0.026	
Anti-platelet	(%)	 2	(25)	 21	(72.4)	 10	(90.9)	 0.009	
 
(The significance in age is between the EVAR and open groups) 
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5.3 Data collection: 
The following clinico-pathological data have been collected prospectively: Patients’ 
demographics - age and sex; co-morbidity and medications; diameter of the 
aneurysm measured by pre-operative CT scan; peri-operative bloods results; 
procedural details; post-operative data including imaging investigations, re-
interventions, complications and mortality; cardiovascular morbidity and mortality.  
 
5.4 Blood sample collection: 
A resting venous blood sample was drawn from an ante-cubital fossa vein without 
tourniquet at the following time points for haemostatic assays: pre-procedure, days 1 
and 1, 6 and 12 months post-procedure. Blood was sampled into a standard syringe 
without the application of suction, and then transferred to specific tubes. A 2.7ml 
sample was collected into EDTA anticoagulant, a 3ml sample into sodium citrate 
anticoagulant, a 9ml sample into a tube containing clot activator and a 4.5 ml sample 
into strong acid citrate. Samples were immediately transferred to the laboratory 
where they were centrifuged within 30 minutes of collection at 3,500 revolutions per 
minute for 15 minutes at a temperature of 4 C. Plasma and serum were separated 
and stored at -80 C for later batch analysis. 
 
5.5 Assay Methods: 
Tests were performed using the fully automated, multi-batch and multi-test Triturus® 
EIA Analyzer (Grifols USA, LLC, Los Angeles, CA) according to the manufacturer’s 
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instructions. The following markers have been tested for all patients at all time 
points.  
 
5.5.1 Markers of Coagulation:  
PF 1+2 (normal range 0.4-1.1 nmol/l) (USCN Life Science Inc, Wuhan, China) and 
TAT (normal range 1-4.1 μg/l) (Enzygnost TAT Micro, Siemens Healthcare 
Diagnostics Inc, Deerfield, Ill) were measured.  
 
5.5.2 Markers of fibrinolysis:  
PAI activity (normal range 1-7 U/ml) (Technozym PAI-1 Actibind; Technoclone Ltd, 
Surrey, United Kingdom) and t-PA antigen (normal range 2-8 ng/ml) and activity (0 
U/ml) (t-PA Combi Actibind; Technoclone Ltd) were measured. 
 
5.5.3 Markers of platelet and endothelial activation and inflammation:  
sP-selec (normal range 92-212 ng/ml) was measured as a marker of platelet 
activation, sE-selectin (normal range 17.5-88.1 ng/ml) as a marker of endothelial 
cell (EC) activation (IBL International GMBH, Hamburg, Germany), and highly 
sensitive C-reactive protein (hs-CRP) was measured as a marker of the 
inflammatory response. 
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5.5.4 Markers of renal function:  
Cyst c (normal range 0.53-1.05 mg/l) was measured using the Turbidimetric Human 
Cyst C Kit for the Roche Modular P unit (manufactured by The Binding Site Ltd., 
Bham, UK), whereas sCr (normal range 60-110 µmol/l) was analysed using Kinetic 
colorimetric assay (Jaffe) performed on a Roche Modular P Unit. eGFR 
(ml/min/1.73m2) was calculated at the same time points using the validated MDRD 
formula.  
 
5.6 Power Calculation: 
Statistical advice has been sought from the chief statistician at University Hospital 
Birmingham regarding study sample size calculation. Based upon previously 
published data by this institution, a minimum sample size of 17 patients was required 
to demonstrate a similar degree of haemostatic improvement following EVAR as was 
found after open surgical repair with a power of 80% (β-error =0.8) and a 
significance of <0.05 (α-error=0.05).  
 
5.7 Statistical Analysis: 
As for previous studies from this institution, statistical assistance was sought from 
the Department of Public Health and Epidemiology at the University of Birmingham. 
The calculations were performed using SPSS for Windows (version 16.0; SPSS Inc., 
Chicago, III) and GraphPad Prism 5 for Windows (Version 5.03; GraphPad Software 
Inc., CA). A p value of less than 0.05 was considered statistically significant. Unless 
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indicated, median values with inter-quartile range (IQR) were used for continuous 
variables. 
The groups were compared using Friedman test. The change over time was 
analysed using Dunn’s multiple comparison test and Wilcoxon signed rank paired 
test. In order to determine the effects of co-variables on the results, data were log 
transformed in order to follow normal distribution and analysis was performed using 
the parametric independent-sample t-test. Correlation between co-factors was 
performed using the log transformed data using Pearson correlation coefficient.  
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Chapter 6 
Changes in coagulation and fibrinolytic system following EVAR 
6.1 Introduction: 
Abdominal aortic aneurysm (AAA) is associated with deranged haemostasis, 
endothelial cell (EC) and platelet activation, and cardiovascular morbidity and 
mortality.(5, 7, 9-20) We have shown recently that patients with AAA exhibit 
increased thrombin generation and activity as well as increased fibrin turnover.(200) 
Although these derangements appear to be correlated with aneurysm size,(20) 
increased fibrin turnover is also found in patients with small AAA.(5) This may show 
that haemostatic derangement is related to the size of intra-sac thrombus than 
aneurysm size.(21) 
Both open surgical (OR) and endovascular (EVAR) repair of AAA are associated 
with increased thrombin generation and relative hypo-fibrinolysis in the immediate 
peri-operative period.(19, 22, 34, 43, 154, 200, 201) The resultant pro-thrombotic 
diathesis after OR and EVAR may account for the high level of peri-operative 
thrombotic complications. It was found that the haemostatic response is significantly 
reduced in the long term following OR but not normalized.(153) However, it remains 
unclear what happens in the long term following EVAR and what the clinical 
consequences of these haemostatic abnormalities might be for patients.  
The aim of this study, therefore, was to examine thrombin generation, fibrinolysis, 
and EC, platelet activation and inflammatory response for up to 12 months following 
elective EVAR. 
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6.2 Methods:  
Twenty-nine patients (27 men and 2 females) of mean age 77 years (range, 55-89 
years) and with AAA of mean diameter 6.9 cm (range, 5.5-10 cm) underwent 19 
standard and 10 fenestrated EVARs under general (n=12) or epidural (n=17) 
anaesthesia. Patients’ demographics are shown in (Table 7).  
All patients received bolus injection of intravenous heparin (3000 units for standard 
and 5000 units for fenestrated EVAR) prior to inserting the stent graft. Further 
boluses of heparin were given during the operation to maintain the activated clotting 
time above 200. Twenty-two patients were taking aspirin (75 mg daily), 14 were 
being treated for hypertension, 16 had a history of ischemic heart disease, and 14 
had renal impairment.   
Venous blood was collected from the ante-cubital fossa without tourniquet into 
sodium citrate tubes before induction of anaesthesia and at 1 day and 1, 6, and 12 
months post-operatively. Samples were centrifuged for 15 minutes at 3500 
revolutions per minute within 30 minutes of collection; plasma was isolated, aliquot, 
and stored in the freezer at -80°C for later batch analysis. 
 
Markers of thrombin generation and neutralization. 
Prothrombin fragment (PF) 1+ 2 (USCN Life Science Inc, Wuhan, China) and 
thrombin-antithrombin complexes (TAT; Enzygnost TAT Micro, Siemens Healthcare 
Diagnostics Inc, Deerfield, Ill) were measured. 
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Markers of fibrinolysis.  
Plasminogen activator inhibitor (PAI) activity (Technozym PAI-1 Actibind; 
Technoclone Ltd, Surrey, United Kingdom) and tissue plasminogen activator (t-PA) 
antigen and activity (t-PA Combi Actibind; Technoclone Ltd) were measured. 
 
Markers of platelet and endothelial activation and inflammation.  
Soluble (s)P-selectin was measured as a marker of platelet activation, sE-selectin as 
a marker of EC activation (202) (IBL International GMBH, Hamburg, Germany), and 
highly sensitive C-reactive protein (hs-CRP) was measured as a marker of the 
inflammatory response. 
Tests were performed using the fully automated, multibatch and multi-test Triturus 
EIA Analyzer (Grifols USA, LLC, Los Angeles, Calif) according to the manufacturer’s 
instructions. 
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6.3 Results:  
6.3.1 Patients and stent grafts 
Twenty-three patients had a Zenith (Cook Inc., Bloomington, Ind.) and six had an 
Excluder (WL Gore Inc., Flagstaff, AZ). Standard EVAR was used for patients with 
infra-renal AAA (19 patients) and F-EVAR was used to treat juxta-renal, supra-renal 
and thoraco-abdominal AAA (10 patients). All the grafts were implanted successfully 
with no graft failure or graft related mortality encountered during the 12-month 
period. 
Three patients required re-intervention at six months post-operatively. They 
developed claudication-type symptoms due to stenosis in one limb of the graft. This 
was diagnosed clinically and confirmed using duplex scanning. Two patients 
required angioplasty and the third patient required combined common femoral artery 
endarterectomy and angioplasty. Two other patients developed type II endoleak. 
This was detected by duplex and confirmed by CT scan at 6 months follow up visit 
with no intervention required. Changes in different markers are shown in table 10. 
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Table 10: Changes in different markers over time (median and IQR) 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
PF1+2  
(0.4-1.1 
nmol/l) 
 
2.1 (1.5-3.7) 2 (1.4-2.9) 2.1 (1.6-3.4) 1.9 (1.2-2.5)* 1 (0.7-2)* 
TAT  
(1-4.1 μg/l) 
 
6.2 (4.4-15.6) 14 (11-
24.6)* 
8.1 (5.4-14.3) 8.9 (5.1-
11.6) 
7 (5.1-11) 
PAI activity  
(1-7 U/ml) 
 
4.9 (0.3-6.8) 8.5 (0.3-
10.6)* 
0.3 (0.3-3)* 0.3 (0.3-4)* 5.7 (3.8-
7.7) 
t-PA antigen  
(2-8 ng/ml) 
 
3.4 (2.6-4.4) 5.1 (3.1-
6.4)* 
3.5 (2.4-5.4) 1.2 (1-2.2)* 3.4 (2.4-
4.5) 
t-PA activity  
(0 U/ml) 
 Mean(SD) 
 
0 (0) 0 (0) 0.046 (0.09)* 0.023 (0.06)* 0 (0) 
sP-selec  
(92-212 
ng/ml) 
 
71 (61-86) 80 (61-93) 113 (80-
141.5)* 
110 (73.5-
139.5)* 
87 (61-
116)* 
E-selec  
(17.5-88.1 
ng/ml) 
 
14 (9-18) 24.5 (12.5-
42.5)* 
15 (9-22) 52 (23.5-
59.5)* 
38 (24-42)* 
hsCRP 
(mg/l) 
 
4.3 (1.5-12.75) 82.2 (53-
105.5)* 
7 (3.3-19) 4.3 (2.1-
16.3) 
2.7 (1.2-
11.6) 
*p<0.05 against pre-operative values. IQR: inter-quartile range. SD: standard 
deviation. 
The groups were compared using Friedman test. The change over time was 
analysed using Dunn’s multiple comparison test and Wilcoxon signed rank paired 
test. In order to determine the effects of co-variables on the results, data were log 
transformed in order to follow normal distribution and analysis was performed using 
the parametric independent-sample t-test. 
 
 
 
 
66	
	
6.3.2 Markers of coagulation 
PF1+2: The median (IQR) pre-operatively was significantly higher than the normal 
range 2.1 nmol/l (1.5-3.7). At 24 hours and one month, it stayed significantly higher 
than normal, but, there was no significant change from the baseline level (2 nmol/l 
(1.4-2.9) and 2.1 nmol/l (1.6-3.4) respectively). This was followed by significant drop 
in PF1+2 at six months (1.9 nmol/l (1.2-2.5), p=0.035), however, still significantly 
higher than the normal range. At 12 months, it dropped further to within the normal 
range (1 nmol/l (0.7-2), p<0.001) and was significantly lower than the baseline. 
(Figures 3) 
 
TAT: The median (IQR) pre-operatively was significantly higher than the normal 
range 6.2 μg/l (4.4-15.6). It increased significantly at 24 hours in response to the 
operation (14 μg/l (11-24.6), p<0.005). This was followed by return to the pre-
operative level at one (8.1 μg/l (5.4-14.3)), six (8.9 μg/l (5.1-11.6)) and 12 months (7 
μg/l (5.1-11)) post-operatively. TAT remained higher than the normal range through 
the whole length of the study.  (Figures 4) 
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Figure 3: Changes in PF 1+2, horizontal lines represent the normal range 
The median (IQR) pre-operatively was significantly higher than the normal range 2.1 
nmol/l (1.5-3.7). At 24 hours and one month, it stayed significantly higher than 
normal, but, there was no significant change from the baseline level (2 nmol/l (1.4-
2.9) and 2.1 nmol/l (1.6-3.4) respectively). This was followed by significant drop in 
PF1+2 at six months (1.9 nmol/l (1.2-2.5), p=0.035), however, still significantly higher 
than the normal range. At 12 months, it dropped further to within the normal range (1 
nmol/l (0.7-2), p<0.001) and was significantly lower than the baseline. 
 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
PF1+2  
(0.4-1.1 
nmol/l) 
2.1 (1.5-3.7) 2 (1.4-2.9) 2.1 (1.6-3.4) 1.9 (1.2-2.5)* 1 (0.7-2)* 
*p<0.05 against pre-operative values. 
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Figure 4: Changes in TAT 
The median (IQR) pre-operatively was significantly higher than the normal range 6.2 
μg/l (4.4-15.6). It increased significantly at 24 hours in response to the operation (14 
μg/l (11-24.6), p<0.005). This was followed by return to the pre-operative level at one 
(8.1 μg/l (5.4-14.3)), six (8.9 μg/l (5.1-11.6)) and 12 months (7 μg/l (5.1-11)) post-
operatively. TAT remained higher than the normal range through the whole length of 
the study. 
 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
TAT  
(1-4.1 μg/l) 
 
6.2 (4.4-15.6) 14 (11-
24.6)* 
8.1 (5.4-14.3) 8.9 (5.1-
11.6) 
7 (5.1-11) 
*p<0.05 against pre-operative values. 
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6.3.3 Markers of fibrinolysis 
PAI: The median (IQR) of PAI was within the normal range 4.9 U/ml (0.3-6.8). It 
increased significantly at 24 hours to above the normal level (8.5 U/ml (0.3-10.6), 
p=0.001). This was followed by significant drop at one (0.3 U/ml (0.3-3), p<0.001) 
and six months (0.3 U/ml (0.3-4), p=0.002) with the median below the normal range. 
At 12 months, there was a significant increase in PAI to return to the baseline level 
5.7 U/ml (3.8-7.7) (p=0.008) to stay within the normal range. (Figures 5) 
 
t-PA antigen: The median (IQR) of t-PA antigen was within the normal range 3.4 
ng/ml (2.6-4.4). t-PA antigen increased significantly at 24 hours (5.1 ng/ml (3.1-6.4), 
p<0.001) and then returned to the baseline level at one month. This was followed by 
significant reduction at six months (1.2 ng/ml (1-2.2), p<0.001) and return back to 
pre-operative values at 12 months. t-PA antigen stayed within the normal range 
during the whole period of the study. (Figures 6) 
 
t-PA activity: t-PA activity was 0 U/ml pre-operatively. There was no change at 24 
hours post-operatively. This was followed by significant increase at one (p<0.005) 
and six months (p=0.03) and return to pre-operative level at 12 months. (Figures 7) 
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Figure 5: Changes in PAI activity 
The median (IQR) of PAI was within the normal range 4.9 U/ml (0.3-6.8). It increased 
significantly at 24 hours to above the normal level (8.5 U/ml (0.3-10.6), p=0.001). 
This was followed by significant drop at one (0.3 U/ml (0.3-3), p<0.001) and six 
months (0.3 U/ml (0.3-4), p=0.002) with the median below the normal range. At 12 
months, there was a significant increase in PAI to return to the baseline level 5.7 
U/ml (3.8-7.7) (p=0.008) to stay within the normal range. 
 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
PAI activity  
(1-7 U/ml) 
 
4.9 (0.3-6.8) 8.5 (0.3-
10.6)* 
0.3 (0.3-3)* 0.3 (0.3-4)* 5.7 (3.8-
7.7) 
*p<0.05 against pre-operative values. 
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Figure 6: Changes in T-PA antigen 
The median (IQR) of t-PA antigen was within the normal range 3.4 ng/ml (2.6-4.4). t-
PA antigen increased significantly at 24 hours (5.1 ng/ml (3.1-6.4), p<0.001) and 
then returned to the baseline level at one month. This was followed by significant 
reduction at six months (1.2 ng/ml (1-2.2), p<0.001) and return back to pre-operative 
values at 12 months. t-PA antigen stayed within the normal range during the whole 
period of the study. 
 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
t-PA antigen  
(2-8 ng/ml) 
 
3.4 (2.6-4.4) 5.1 (3.1-
6.4)* 
3.5 (2.4-5.4) 1.2 (1-2.2)* 3.4 (2.4-
4.5) 
*p<0.05 against pre-operative values. 
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Figure 7: Changes in t-PA activity 
t-PA activity was 0 U/ml pre-operatively. There was no change at 24 hours post-
operatively. This was followed by significant increase at one (p<0.005) and six 
months (p=0.03) and return to pre-operative level at 12 months. 
 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
t-PA activity  
(0 U/ml) 
 Mean(SD) 
0 (0) 0 (0) 0.046 (0.09)* 0.023 (0.06)* 0 (0) 
*p<0.05 against pre-operative values. 
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6.3.4 Platelet activation  
Pre-operative level of sP-selec was significantly lower than the normal range at 71 
ng/ml (61-86). It stayed below the lower limit of the normal range with no significant 
change at 24 hours post-operatively (80 ng/ml (61-93)). At one month, there was 
significant elevation (113 ng/ml (80-141.5), p<0.001) which remained high at six 
months (110 ng/ml (73.5-139.5), p<0.001). Both levels were within the normal levels. 
There was a significant drop at 12 months from the level of six months (87 vs 110 
ng/ml, p<0.005). The median value at 12 months was down to below the normal 
range, however, higher than the pre-operative level (p=0.008). (Figure 8) 
      
Figure 8: Changes in sP-selectin activity 
 Pre-operative 24 hours 1 month 6 months 12 months  
sP-selec  
(92-212 
ng/ml) 
71 (61-86) 80 (61-93) 113 (80-
141.5)* 
110 (73.5-
139.5)* 
87 (61-
116)* 
*p<0.05 against pre-operative values. 
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6.3.4 Endothelial activation 
sE-selec pre-operatively was found to be lower than the normal level 14 ng/ml (9-
18). There was a significant increase at 24 hours when compared with baseline level 
(24.5 ng/ml (12.5-42.5) vs 14 ng/ml (9-18), p<0.001). This was followed by return to 
pre-operative value at one month (15 ng/ml (9-22)) and significant increase at six (52 
ng/ml (23.5-59.5), p<0.001) and 12 months (38 ng/ml (24-42), p<0.001). (Figure 9) 
            
Figure 9: Changes in sE-selectin activity 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
E-selec  
(17.5-88.1 
ng/ml) 
14 (9-18) 24.5 (12.5-
42.5)* 
15 (9-22) 52 (23.5-
59.5)* 
38 (24-42)* 
*p<0.05 against pre-operative values. 
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6.3.6 Inflammatory response 
hs-CRP increased significantly 24 hours post-operatively in response to the 
operation (82.2 mg/l (53-105.5) vs 4.3 mg/l (1.5-12.75), p<0.001). This was followed 
by a fall down to the baseline levels at one month (7 mg/l (3.3-19)). There was not 
significant change in the level of hsCRP at six (4.3 mg/l (2.1-16.3)) and 12 months 
(2.7 mg/l (1.2-11.6)). (Figure 10) 
              
Figure 10:  Changes in hsCRP activity 
 Pre-operative 
 
24 hours 
 
1 month 
 
6 months 
 
12 months  
 
hsCRP 
(mg/l) 
 
4.3 (1.5-12.75) 82.2 (53-
105.5)* 
7 (3.3-19) 4.3 (2.1-
16.3) 
2.7 (1.2-
11.6) 
*p<0.05 against pre-operative values. 
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6.3.7 Correlation of different markers, aneurysm size and demographics  
Aneurysm size did not correlate with coagulation, fibrinolytic or inflammatory markers 
pre or post-operatively. TAT and PF1+2 did not correlate at any time point. PAI 
activity correlated significantly with t-PA antigen at all time points (p<0.001).  sP-
selec and E-selec did not correlate at any time point. Correlation with other co-
variables is shown in table 7.  
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6.4 Discussion:  
There has been a concern of developing coagulation disorders following EVAR 
especially the fatal complication of consumptive coagulopathy. Ohara et al (203)  
described fatal DIC in one patient with severe liver disease following EVAR. Cross et 
al (204) reported another case of fatal consumptive coagulopathy following 
technically difficult EVAR. It was believed that leaving the thrombus in the isolated 
aneurysm sac may be the trigger factor for this coagulation derangement. Hollier et 
al (205) described a non-resective technique for high risk patients with AAA. They 
ligated the proximal and distal sides of the aneurysm, leaving the contained 
thrombus behind, and performed an axillo-bifemoral bypass to exclude the 
aneurysm. Schwartz et al (206) reported that DIC may complicate non-resective 
treatment of AAA.  
The results in this study show that patients with asymptomatic AAA have pre-
operative hyper-coagulable state as demonstrated by higher than normal PF1+2 and 
TAT. (Figures 3 & 4) This result is similar to previous studies which found activated 
coagulation pre-operatively in patients with AAA.(5, 18, 20, 22, 34, 43, 201) Our 
results show that pre-operative TAT level was significantly higher in patients >75 
years (p=0.001). Unlike previous studies, we did not find correlation between pre-
operative TAT and PF1+2 with aneurysm size.  
The different behaviour of PF1+2 and TAT in response to EVAR and the lack of 
correlation between these two markers before and after the operation suggest they 
represent different responses. High levels of PF1+2 and TAT indicate excess 
thrombin production and neutralization respectively. PF1+2 remained unchanged 
from baseline at 24 hours and one month post-operatively indicating no increase in 
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thrombin generation in response to EVAR. At 6 months, it decreased significantly; 
however, it was higher than normal values. At 12 months, PF1+2 dropped 
significantly below the pre-operative level to reach the normal range suggesting 
normalization of thrombin generation at one year post EVAR. This means that the 
presence of the thrombus in the isolated aneurysm sac does not induce thrombin 
production as previously thought.  
The significant increase in TAT at 24 hours post-operatively may be explained by 
increased binding with anti-thrombin III in response to manipulation during insertion 
of the stent graft. Shimazaki et al (201) and Monaco et al (154) showed significant 
reduction in anti-thrombin III and significant increase in TAT on the first post-
operative day. They showed return of anti-thrombin III to baseline on the first week 
after the operation and then remained unchanged. Results similar to ours were 
observed at short term in previous studies.(22, 43, 201) However, this is the first 
report to describe normalization of thrombin generation following EVAR which is 
detected one year following the operation. This may be due to lack of reports looking 
at these changes at the long term. The combination of no increase in thrombin 
generation and increased thrombin neutralization following EVAR may be protective 
against cardiovascular complications and thrombo-embolic disorders in this group of 
patients.  
Similar to previous studies, we found pre-operative PAI activity, t-PA antigen and 
activity within normal range suggestive of normal fibrinolysis in patients with 
AAA.(20, 22, 34) We found t-PA antigen significantly low in older patients (p=0.025). 
This, together with higher TAT, agrees with earlier report that old age is associated 
with activation of the coagulation and fibrinolytic activity.(14) Following EVAR, PAI 
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activity increased significantly on the first post-operative day higher than normal 
range indicating hypo-fibrinolysis. There was significant drop to less than normal 
values noticed at one and six months suggestive of hyper-fibrinolysis. At 12 months, 
PAI activity returned to the baseline level within the normal range. Aho et al (22) 
described significant increase in PAI activity at day one post-operatively, temporary 
decrease at day three, increase again at day seven and return to pre-operative level 
at three months.  
t-PA antigen increased significantly at 24 hours, though within the normal range. 
There was significant drop below normal range at six months and return to baseline 
at 12 months. t-PA activity was undetected pre-operatively and 24 hours following 
EVAR. It increased significantly at one month, remained high at six months and was 
undetectable again at 12 months post-operatively. The post-operative fibrinolytic 
response showed low fibrinolytic activity on the first post-operative day which may be 
due to the surgical trauma, high fibrinolytic activity at one and six months and return 
to the normal fibrinolytic activity 12 months following EVAR. The expected correlation 
between PAI activity and t-PA antigen at all time points indicate the validity of the 
analysis.  
Platelet activity, as represented by sP-selec, was subnormal pre-operatively and 24 
hours after the operation. Patients with IHD and those who were on anti-platelet 
treatment before the operation had significantly lower sP-selec at these two time 
points. There was significant increase at one and six months followed by significant 
drop at 12 months. However, one year after EVAR, sP-selec was significantly higher 
than the baseline level. The significant increase in platelet activity may justify giving 
dual anti-platelet therapy to patients following EVAR especially during the first year 
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after the operation. Aho et al described significant reduction in sP-selec on third 
post-operative day with increase above the baseline three months following EVAR. 
The significant increase in sE-selec that was observed on the first post-operative day 
could be due to the manipulation during inserting the stent graft. The absence of 
correlation between sP-selec and sE-selec at all time points and their different 
responses to EVAR indicated that they did not arise from the same source.  
The increase in hs-CRP experienced on day one, occurred in response to the 
surgical trauma. However, there was no significant difference in the inflammatory 
response, from the baseline level, at one, six and 12 months post-operatively. 
Previous studies showed detected maximum increase in CRP on the second and 
third days following EVAR.(22, 43) 
 Patients with infra-renal AAA had significantly lower pre-operative hs-CRP 
(p<0.003). When the inflammatory response to EVAR was compared between 
patients, those who had F-EVAR had significantly higher response at one (p=0.012), 
six (0.009) and 12 (0.021) months than patients who had standard EVAR. This may 
indicate that the inflammatory response is related to the extent of the aneurysm 
rather than the size. It has been confirmed before that CRP correlated with the 
volume of the intra-mural thrombus. 
We found that type of the stent graft affected the coagulation response following 
EVAR. Patients who had Zenith graft had significantly higher TAT than patients who 
had Excluder stents at one (p<0.001), six (p=0.03) and 12 (p=0.008) months 
suggesting more thrombin neutralization. This may be related to the porosity of the 
graft material. They also had higher hs-CRP at one, six and 12 months (p<0.05, 
0.005 and 0.003 respectively). However, after adjustment to patients with infra-renal 
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AAA, there was no statistical difference in the inflammatory response between 
patients who had Zenith from those who had Excluder grafts.   
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6.5 Conclusion:  
This report shows for the first time normalization of coagulation mechanism one year 
following EVAR. The unchanged thrombin production and increased thrombin 
neutralization experienced on the first post-operative day may be protective at the 
early stages following EVAR. The normalization of thrombin generation and 
fibrinolytic response one year after the operation may represent a decrease in the 
incidence of thrombo-embolic events that is high in patients with AAA. Following 
EVAR, dual anti-platelet therapy may be advisable to counteract the increase in 
platelet activity experienced during the first post-operative year.   
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Chapter 7 
Effect of EVAR and OAR on thrombin generation, fibrinolysis and 
inflammatory response 
7.1 Introduction:  
Abdominal aortic aneurysm (AAA) is a chronic inflammatory condition associated 
with activation of coagulation.(17-19, 149) The aetiology of these changes is poorly 
understood but may be related to smoking, the presence of peripheral arterial 
disease leading to repeated lower limb ischemia and reperfusion, and the biological 
activity of the aortic wall and/or intra-luminal thrombus.(14-16) Previous studies have 
suggested an association between the observed haemostatic derangements, micro-
vascular and macro-vascular thrombosis, and the development of complications 
such as myocardial infarction, multiple organ failure, and venous and arterial 
thromboembolism.(11-13) Open aneurysm repair (OAR) and endovascular 
aneurysm repair (EVAR) of AAAs have been shown to be associated with an 
exacerbation of these haemostatic derangements in the immediate peri-operative 
period.(18, 34, 200) By contrast, the medium- and long term changes in coagulation 
and fibrinolysis after OAR and EVAR are poorly defined.(153)  
The purpose of this study, therefore, was to investigate, we believe for the first time, 
the medium-term effects of EVAR and OAR on thrombin generation, neutralization, 
and fibrinolysis. 
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7.2 Patients and Methods:  
7.2.1 Group 1:  
Twenty-nine patients (27 men) of mean age 77 years (range, 55-89 years) were 
studied before (pre-operative) and after EVAR (post-EVAR) for asymptomatic AAA of 
mean diameter 6.9 cm (range, 5.5-10 cm) between July 2008 and April 2009. 
 
7.2.2 Group 2:  
Eleven patients (nine men) were studied at mean of 16 months (range, 7-21 months) 
after OAR (post-OAR). Mean age at the time of blood sampling was 72 years (range, 
58-85 years). All patients who underwent OAR were anatomically unsuitable for 
standard EVAR. 
 
7.2.3 Group 3:  
Eight age-matched controls (AMC) (four men) of mean age 73 years (range, 65-90 
years) without AAA as documented by computed tomography (CT) scan, performed 
for the investigation of a nonvascular condition, were recruited. Specifically, five 
patients had normal follow-up CT scans 2 years after resection for colon cancer, and 
three patients had normal CT scans for nonspecific abdominal pain. None of these 
patients was found to have any significant pathology. 
Exclusion criteria included vascular or nonvascular surgical or endovascular 
procedure within the 3 months before EVAR or blood sampling; known inherited or 
acquired thrombophilia; known disorders of fibrinolysis or platelet function; and 
anticoagulation with vitamin K antagonists. Blood sampling and assays. Venous 
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blood samples were taken from an antecubital fossa vein without tourniquet 
immediately before and 12 months after EVAR. Patients who underwent OAR and 
AMC had a single sample taken. Samples were centrifuged for 15 minutes at 3500 
rpm within 30 minutes of collection; plasma was isolated, aliquoted, and stored at -
80°C for later batch analysis. Levels of prothrombin fragment (PF)1+2, a marker of 
thrombin generation, (USCN Life Science, Wuhan, China) and thrombin-antithrombin 
(TAT) complex, a marker of thrombin neutralization (Enzygnost TAT micro, Siemens 
Healthcare Diagnostics, Deerfield, Ill) were measured using enzyme-linked 
immunosorbent assays. Tissue-plasminogen activator (t-PA) antigen (t-PA Combi 
Actibind, Technoclone Ltd, Surrey, UK) and plasminogen activator inhibitor (PAI) 
activity (Technozym PAI-1 Actibind, Technoclone Ltd, Surrey, UK) were assayed as 
measures of fibrinolysis. 
PF1+2, TAT, t-PA antigen, and PAI activity enzyme linked immuno-sorbent assays 
were performed using the Triturus EIA Analyzer (Grifols, USA, LLC, Los Angeles, 
Calif) according to the manufacturer’s instructions. 
 
7.2.4 Statistical analysis:  
Analyses were performed using SPSS for Windows (version 16.0; SPSS Inc, 
Chicago, Ill) and GraphPad Prism 5 for Windows (version 5.03; GraphPad Software, 
San Diego, Calif). Data were log transformed, as they were not normally distributed. 
Median and Inter-quartile range values were calculated for continuous variables and 
categorical data were expressed as absolute numbers with percentages. Differences 
between study groups were assessed by the Fisher exact test for categorical 
variables and by Mann-Whitney U tests for continuous variables. Correlation was 
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assessed by the Pearson method. Results were considered statistically significant 
when P values were < 0.05. 
 
7.3 Results:  
All EVAR procedures were undertaken uneventfully with AAA sac exclusion being 
confirmed by completion angiography and post procedure CT. One patient 
developed acute coronary syndrome on the day of the operation and showed 
relatively higher PF1 2 levels. By 6 months, three patients developed unilateral graft 
limb stenosis and had required re-intervention for claudication; two underwent 
balloon angioplasty and a third had common femoral artery endarterectomy and 
patch angioplasty. Two other patients developed asymptomatic type II endoleak, 
which were treated conservatively. None of the patients who required intervention or 
those who developed endoleak showed significant pro-coagulant results. None of the 
patients developed deep vein thrombosis, pulmonary embolism, or post-implantation 
inflammation syndrome. All OARs were undertaken uneventfully without major 
complications and none of the patients required re-intervention in the period between 
surgery and blood sampling. In group 3, one patient who had CT scan for abdominal 
pain was found to have gall bladder stones and no other significant pathology was 
found in the remaining seven patients. Laboratory results of different markers are 
shown in Table 11.  
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Table 11: Laboratory results of different markers in the three groups (median and 
IQR). Normal range is according to the manufacture’s guidelines.  
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
PF1+2  
(0.4-1.1 nmol/l) 
 
0.8 (0.7-1.4) 2.2 (1.6-3.5)* 1 (0.7-1.9) 0.8 (0.6-1.6) 
TAT  
(1-4.1 μg/l) 
 
4.6 (2.9-11.3) 6.2 (4.4-15.6) 7 (5.1-11) 5.6 (5-13.3) 
PAI activity  
(1-7 U/ml) 
 
6.4 (3.4-8.7) 4.9 (0.3-6.7) 5.7 (3.8-7.7) 7.5 (5.7-8.3)* 
t-PA antigen  
(2-8 ng/ml) 
 
4.4 (3-4.8) 3.4 (2.6-4.4) 3.6 (2.4-4.5) 4 (3-5) 
hs-CRP 
(mg/l) 
 
1.5 (0.63-4.8) 4.3 (1.5-
12.8)* 
2.7 (1.2-11.6) 3.8 (1.2-6.7) 
* p-value <0.05 
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7.3.1 Markers of coagulation 
PF1+2 The median and IQR of PF1+2 was within the normal range in AMC (0.8 (0.7-
1.4)). It was significantly higher in patients with AAA pre-operatively than in the AMC 
group (0.8 (0.7-1.4) vs 2.2 (1.6-3.5), p value = 0.0078). Post-EVAR and post-OAR 
results were significantly lower than pre-operative level (2.2 (1.6-3.5) vs 1 (0.7-1.9) 
and 0.8 (0.6-1.6), p value <0.001 and 0.0046 respectively). The level of PF1+2 post-
EVAR was not significantly different from post-OAR. PF1+2 results in both groups 
were not statistically significantly different from the level in AMC. (Figure 11) 
 
TAT The median levels of TAT in the four groups were higher than the normal range. 
However, there was no statistical significance between the four groups. (Figure 12) 
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Figrue11: Changes in PF1+2 among the groups.  
The median and IQR of PF1+2 was within the normal range in AMC (0.8 (0.7-1.4)). It 
was significantly higher in patients with AAA pre-operatively than in the AMC group 
(0.8 (0.7-1.4) vs 2.2 (1.6-3.5), p value = 0.0078). Post-EVAR and post-OAR results 
were significantly lower than pre-operative level (2.2 (1.6-3.5) vs 1 (0.7-1.9) and 0.8 
(0.6-1.6), p value <0.001 and 0.0046 respectively). The level of PF1+2 post-EVAR 
was not significantly different from post-OAR. PF1+2 results in both groups were not 
statistically significantly different from the level in AMC. 
 
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
PF1+2  
(0.4-1.1 nmol/l) 
0.8 (0.7-1.4) 2.2 (1.6-3.5)* 1 (0.7-1.9) 0.8 (0.6-1.6) 
* p-value <0.05 
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Figure 12: Changes in TAT among the groups.  
The median levels of TAT in the four groups were higher than the normal range. 
However, there was no statistical significance between the four groups. 
 
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
TAT  
(1-4.1 μg/l) 
 
4.6 (2.9-11.3) 6.2 (4.4-15.6) 7 (5.1-11) 5.6 (5-13.3) 
* p-value <0.05 
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7.3.2 Markers of fibrinolysis  
PAI activity There was no difference in the level of PAI activity between AMC with 
patients with AAA pre-operative (6.4 (3.4-8.7) vs 4.9 (0.3-6.7), p value>0.5). There 
was no significant change in PAI activity one year following EVAR (5.7 (3.8-7.7)). 
However, the level was significantly higher post-OAR than pre-operatively (7.5 (5.7-
8.3) vs 4.9 (0.3-6.7), p value 0.03). (Figure 13) 
 
t-PA antigen The results were within the normal range with no significant difference 
between the four groups. (Figure 14) 
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Figure 13: Changes in PAI activity among the groups.  
There was no difference in the level of PAI activity between AMC with patients with 
AAA pre-operative (6.4 (3.4-8.7) vs 4.9 (0.3-6.7), p value>0.5). There was no 
significant change in PAI activity one year following EVAR (5.7 (3.8-7.7)). However, 
the level was significantly higher post-OAR than pre-operatively (7.5 (5.7-8.3) vs 4.9 
(0.3-6.7), p value 0.03). 
 
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
PAI activity  
(1-7 U/ml) 
 
6.4 (3.4-8.7) 4.9 (0.3-6.7) 5.7 (3.8-7.7) 7.5 (5.7-8.3)* 
* p-value <0.05 
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Figure 14: Changes in t-PA antigen among the groups. 
The results were within the normal range with no significant difference between the 
four groups. 
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
t-PA antigen  
(2-8 ng/ml) 
 
4.4 (3-4.8) 3.4 (2.6-4.4) 3.6 (2.4-4.5) 4 (3-5) 
* p-value <0.05 
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7.3.3 Inflammatory Markers  
hs-CRP The median and IQR of hs-CRP in patients with AAA pre-operatively was 
higher than AMC 4.3 (1.5-12.8) vs 1.5 (0.63-4.8), p value 0.024). No significant 
difference was found between post-EVAR and post-OAR groups. (Figure 15) 
 
Figure 15: Changes in hsCRP among the groups. 
Marker  
(Normal range) 
AMC (n=8) EVAR (n=29) 
    Pre-op            Post-EVAR 
OAR (n=11) 
hs-CRP 
(mg/l) 
 
1.5 (0.63-4.8) 4.3 (1.5-
12.8)* 
2.7 (1.2-11.6) 3.8 (1.2-6.7) 
* p-value <0.05 
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7.4 Discussion: 
EVAR is associated with significantly lower peri-operative morbidity and mortality 
than OAR.(36, 37, 39) However, this benefit is lost six months following the 
operation.(207, 208) This might be related to continuous coagulopathy at the 
medium and long term follow up. There is very little information comparing the 
changes in the haemostatic mechanism at the medium and long term following 
EVAR and OAR.  
The present study confirms that patients with AAA exhibit a hyper-coagulable state 
compared to AMC. This is confirmed by the significant difference between PF1+2 in 
pre-operative patients and the control group. The significant drop in PF1+2 one year 
following EVAR and OAR and the finding that it was not different from AMC group 
might suggest that the increase in PF1+2 pre-operatively was related to AAA. TAT 
was not different between the four groups. This might suggest that thrombin 
neutralization is not related to AAA and is related to other factors like age, 
atherosclerosis and smoking.(14-16) Our PF1+2 results match the results of 
Holmberg et al (153), however, TAT results were different. The difference in TAT 
results may be related to their AMC group constituted of healthy subjects with no 
history of cardiovascular or peripheral vascular diseases.  
 PAI activity and t-PA antigen were within the normal range and not different in both 
AMC and pre-operative groups. This represents relative hypo-fibrinolysis in patients 
with AAA as you would expect increased fibrinolysis secondary to increased 
thrombin generation. One year post EVAR, PAI was not different from AMC and pre-
operative groups. However, one year post OAR, it was significantly higher than pre-
operative group with the median just above the normal range (Figure 13). This might 
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lead to less fibrinolysis in this group of patients.  t-PA antigen was not different post-
EVAR and post-OAR from the AMC and pre-operative. These results are similar to 
Holmberg et al.(153) 
Some reports described that EVAR is associated with increased systemic 
inflammatory response and prothrombotic coagulopathy equal if not greater than that 
witnessed after OAR at the immediate post-operative period.(42, 154) We found that 
one year following EVAR and OAR the coagulation mechanism and the inflammatory 
response are similar and not different from the AMC.  
Similar to others (18, 153), we found that removal (as in OAR) or exclusion (as in 
EVAR) of the intra-aneurysm thrombus from the circulation resulted in correction of 
the inflammatory and pro-coagulant drive found in patients with AAA. This might 
confirm the importance of the intra-aneurysm thrombus in the inflammatory and pro-
thrombotic diathesis associated with AAA.(21, 22, 128, 153) It has been suggested 
that the presence of type II endoleak may regain the contact between the circulation 
and the intra-sac thrombus resulting in deranged haemostasis.(200) 
Although the marker of thrombin generation has been normalized one year following 
EVAR and OAR, thrombin inactivation and fibrinolysis have not had the same 
response. This may be explained by the presence of atherosclerosis and age. 
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7.5 Conclusion: 
AAA exhibits a significant hyper-coagulable and hypo-fibrinolytic state. This is 
corrected one year following EVAR and OAR. The increase in thrombin generation 
reported previously in the immediate peri-operative period after EVAR and OAR 
does not continue on the medium term. Long follow up is recommended to find out 
whether the correction of coagulopathy is maintained or lost at the long term and to 
find the relation of these changes with cardiovascular morbidity and mortality. 
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Chapter 8 
Assessment of Renal Function using Cystatin C 
8.1 Introduction:  
The effect of EVAR on renal function remains uncertain. Early reports showed a 
significant increase in serum creatinine (sCr) and reduction in creatinine clearance 
(CrC) after EVAR.(64, 65, 157-159) sCr levels only increase significantly when 
glomerular filtration rate (GFR) is reduced by more than 50%,(173) and may be 
affected by several non-renal factors (e.g., diet, gender, muscle mass, surgical 
intervention, numerous drugs). 
Cystatin C (Cyst C) is a low-molecular-weight plasma protein that is synthesized and 
secreted by all nucleated human cells and is a more sensitive serum marker of 
subclinical renal injury than sCr, CrC, or GFR.(209-213) However, Cyst C is not the 
standard marker used in clinical practice to detect the renal function after EVAR.  
Previous studies examining the impact of EVAR on renal function using Cyst C have 
shown no deterioration in renal function; one report showed no change in Cyst C 
levels at 3, 6, and 12 months after EVAR, whereas another showed decreased Cyst 
C levels at 24 hours post-operatively, indicating improved glomerular function. (214, 
215) 
Deterioration in renal function after fenestrated EVAR has been reported to be as 
high as 10% to 30%,(91, 98, 165) although this group has never been studied using 
Cyst C. 
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Despite the evidence of sensitivity of Cyst C for detecting minor renal damage, as 
proven in several studies, sCr and estimated GFR are still used as the standard 
markers of renal function. 
The goal of this study, therefore, was to compare the efficacy of Cyst C, sCr, and 
estimated GFR as markers of renal function after standard and fenestrated EVAR. 
 
8.2 Patients and Methods:  
This study included 29 patients (27 men and 2 women) with a mean age of 76.9 
years (range, 55-89 years) undergoing standard (n=19) and fenestrated (n=10) 
EVAR for an abdominal aortic aneurysm (AAA) with a median diameter of 6.2 cm 
(inter-quartile range [IQR], 5.8-7.5 cm). Patients with elevated pre-operative sCr 
were included and provided with peri-operative hydration. Surgery was performed 
under general or epidural anaesthesia. The median contrast load was 75 mL (IQR, 
70e90 mL) of VisipaqueTM for patients who had standard EVAR and 110 mL (IQR, 
105e130 mL) for those who underwent fenestrated EVAR. No patient required peri-
operative blood transfusion. 
Venous blood was collected from the ante-cubital fossa without tourniquet to 
measure serum Cyst C and sCr before induction of anaesthesia, and then again 1 
day and 1, 6, and 12 months post-operatively. 
Blood samples were collected into Vacuette Z Serum Sep Clot Activator tubes 
(Greiner Bio One Ltd., Stonehouse, UK). After centrifugation for 15 minutes at 3500 
revolutions per minute, serum was isolated, aliquoted, and stored at -80C for later 
analysis. 
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Cyst C (mg/L) was measured using the Turbidimetric Human Cystatin C Kit for the 
Roche Modular P unit (The Binding Site Ltd., Birmingham, UK) and sCr (mmol/L) 
was analysed using Creatinine Jaffe Kinetic colorimetric test performed on a Roche 
Modular P unit. 
Estimated GFR (mL/min/1.73m2) was calculated for the same time points using the 
validated Modification of Diet in Renal Disease formula.(168) 
Patients were followed up in the outpatient clinic at 1, 6, and 12 months post-
operatively. Patients underwent a computed tomography (CT) scan at 1 month and 
colour flow duplex ultrasound scans at 6 and 12 months. 
 
Statistical Analysis 
The groups were compared using the Friedman test. The change over time was 
analysed using Dunn multiple comparison test and Wilcoxon signed rank test. Data 
were log transformed to follow normal distribution to determine the effects of co-
variables on the results using the parametric independent-sample t test. Calculations 
were performed using SPSS for Windows (version 16.0; SPSS Inc., Chicago, IL, 
USA) and GraphPad Prism 5 for Windows (Version 5.03; GraphPad Software 
Inc., La Jolla, CA, USA). A P value of less than 0.05 was considered statistically 
significant. 
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8.3 RESULTS:  
Standard EVAR was used for patients with infra-renal AAA (19 patients) and 
fenestrated EVAR was used to treat juxta-renal and supra-renal AAA (10 patients). 
All the endografts were implanted successfully with no deaths or requirement for 
renal replacement therapy during the 12- month period. 
Three patients required re-intervention; two required angioplasty and the third patient 
required combined common femoral artery endarterectomy and angioplasty.  
 
8.3.1 Pre-EVAR renal function 
Prior to EVAR, 14 patients had elevated sCr and 20 had elevated Cyst C. The 
median (IQR) pre-operative values for Cyst C, sCr and eGFR were 1.25 (1.05-1.5) 
mg/l (normal range 0.53-1.05), 106 (88.5-149) μmol/l (normal range 60-110), and 62 
(41.5-73) ml/min/1.73m2 respectively. 
 
8.3.2 Post-EVAR renal function 
Cyst C The median and IQR of Cyst C increased significantly at all time points when 
compared to the pre-EVAR values: 1.35 (1.24-1.66) mg/l at 24 hours, p<0.005; 1.35 
(1.17-1.67) mg/l at one month, p<0.002; 1.42 (1.24-1.67) mg/l at six months, 
p<0.005; and 1.45 (1.25-1.7) mg/l at twelve months, p<0.005.  
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sCr The level of sCr increased significantly at 24 hours (118 μmol/l (99.5-147.5), 
p=0.028) when compared with baseline level.  There was no significant change at 
one, six and twelve months after the operation when compared with the pre-
operative results.  
 
eGFR There was a significant drop in eGFR 24 hours post-operatively (54 
ml/min/1.73m2 (43-66), p=0.04). Following that, there was no significant changesin 
comparison to pre-operative level.  
Changes in Cyst C, sCr and eGFR at pre-operatively, 24 hours, 1, 6 and 12 months 
post-operatively are shown in Figures 16, 17 & 18. 
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Figure 16: Changes in Cyst C. 
The median and IQR of Cyst C increased significantly at all time points when 
compared to the pre-EVAR values: 1.35 (1.24-1.66) mg/l at 24 hours, p<0.005; 1.35 
(1.17-1.67) mg/l at one month, p<0.002; 1.42 (1.24-1.67) mg/l at six months, 
p<0.005; and 1.45 (1.25-1.7) mg/l at twelve months, p<0.005. 
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Figure 17: Changes in sCr. 
sCr increased significantly at 24 hours (118 μmol/l (99.5-147.5), p=0.028) when 
compared with baseline level.  There was no significant change at one, six and 
twelve months after the operation when compared with the pre-operative results. 
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Figure 18: Changes in eGFR. 
There was a significant drop in eGFR 24 hours post-operatively (54 ml/min/1.73m2 
(43-66), p=0.04). Following that, there was no significant changesin comparison to 
pre-operative level. 
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8.3.3 Correlation between renal markers and clinical characteristics 
The correlation between the changes in Cyst C and sCr at different time points is 
shown in Table 12. 
 
Table 12: Correlation between changes in markers of renal function at different time 
points 
 
Calculation  Mean (SD) Pearson coefficient p-value 
Cyst C 24 hrs – Cyst C pre-op 0.05 (0.07) 0.638 <0.001 
sCr 24 hrs - sCr pre-op 0.02 (0.08) 
Cyst C 1 month - Cyst C 24 hrs -0.009 (0.1) 0.896 <0.001 
sCr 1 month - sCr 24 hrs -0.01 (0.1) 
Cyst C 6 moths - Cyst C 1 month 0.02 (0.06) 0.396 0.027 
sCr 6 moths - sCr 1 month -0.009 (0.08) 
Cyst C 12 moths – Cyst C 6 months 0.005 (0.04) 0.263 0.2 
sCr 12 moths – sCr 6 months -0.005 (0.09) 
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8.3.4 Pre-existing chronic kidney disease 
Patients with pre-existing renal impairment (higher than normal sCr) had significantly 
higher Cyst C and sCr and lower eGFR at all time points (p<0.05). In patients with 
normal pre-operative sCr, there was a significant increase at 24 hours (100 μmol/l 
(81-106) vs 89 μmol/l (70-97) p=0.015) and trend toward an increase at 6 months 
(96 μmol/l (81-108) vs 89 μmol/l (70-97) p=0.053) (Figure 19). 
 
 
           
Figure 19: Changes in sCr in patients with no Chronic Kidney Disease.   
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8.3.5 Normal Cyst C 
Patients with normal Cyst C pre-operatively had significant increase in the level of 
Cyst C at all time points (Figure 20). 
 
       
Figure 20: Changes in Cyst C in patients with normal values pre-op. 
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8.3.6 Cyst C following standard and fenestrated EVAR 
Cyst C increased significantly in patients who had standard EVAR at the four time 
points post-operatively (p value 0.009, 0.008, <0.001 and <0.001 respectively) when 
compared with pre-operative values. 
In patients who had F-EVAR, there was a significant increase in Cyst C at 24 hours, 
no significant change at one month and a significant increase at 6 and 12 months (p 
value <0.005, 0.1, 0.01 and <0.005 respectively). (Figure 21) 
 
       
 
Figure 21: Changes in Cyst C in patients who had standard and Fenestrated EVAR. 
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8.4 Discussion:  
Despite the physiological and analytical limitations of sCr (160, 161), the vast 
majority of studies used sCr and CrC as markers of renal function. Cyst C has a 
number of advantages.(209-213) It depends almost completely on the GFR as it is 
freely filtered in the glomerulus, completely re-absorbed and catabolised in the 
proximal tubules. It is considered as a potential replacement for serum creatinine as 
a marker of glomerular filtration as it is more sensitive than sCr in detecting small 
reductions in GFR (25-30%).(209, 213) 
The incidence of renal impairment following EVAR has been reported to be 6-29% 
depending on the presence of pre-operative renal impairment.(162, 163) Other 
studies have failed to demonstrate a significant change in renal function following 
EVAR.(159, 216, 217) 
Two studies used Cyst C to check renal function post-EVAR. Aho et al used Cyst C, 
sCr and CrC as markers of renal glomerular filtration in 24 patients with AAA (15 had 
EVAR and 9 had open repair). They also used N-acetyl-β-D-glucosaminidase as a 
marker of proximal tubular damage. A significant decrease in Cyst C and sCr and 
significant increase in CrC at 24 hours was shown, suggestive of increased 
glomerular filtration. However they demonstrated a significant increase in N-acetyl-β-
D-glucosaminidase at the end of the operation in both groups, suggesting proximal 
tubular damage.(214) Davey et al (215) measured Cyst C, sCr and CrC following 
EVAR (using suprarenal fixation), open aneurysm repair and colorectal resection and 
found no significant difference in Cyst C and CrC following EVAR, open aneurysm 
repair and colon resection at 3, 6 and 12 months post operatively. 
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The current study is the first to show a significant increase in the level of Cyst C 
following EVAR, suggesting renal glomerular injury. Of the 29 patients, 25 showed a 
significant increase in Cyst C levels at 12-months. This increase started 24 hours 
post-operatively and continued for 12 months following the operation and was 
significantly higher than pre-operative values. The difference between our findings 
and those of other studies may be partly explained by the fact that the median 
baseline Cyst C in our patients was higher than the normal range which was not the 
case in the previous two studies that used Cyst C. 
Previous studies have demonstrated that serum levels of Cyst C correlated more 
closely with measured and estimated GFR than sCr.(211) Other studies have shown 
that changes in GFR over time have a stronger correlation with Cyst C than sCr 
especially in patients with early kidney disease, for example diabetics.(184, 185, 
211) In the present study, median Cyst C correlated positively with sCr and 
negatively with eGFR at the five time points. When we looked at the magnitude of 
change between time points for both Cyst C and sCr, these correlated significantly 
for 6 months post-operatively, but not thereafter (Table 12). This, together with the 
significant increase in Cyst C starting from 24 hours post-operatively, suggests that 
Cyst C might be more sensitive in detecting minor renal damage. 
Patients with high sCr pre-operatively did not have significant changes in sCr levels 
post-operatively. This may be due to the fact that patients with pre-operative renal 
impairment had peri-operative hydration and renal protection. This is similar to the 
finding of Parmer et al who found no significant deterioration in sCr following EVAR 
for patients with baseline chronic renal insufficiency.(161) 
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Patients with high Cyst C pre-operatively (20 patients) and seven of the nine patients 
who started with normal Cyst C, showed a significant increase in Cyst C at the end 
of the study period. This indicates that Cyst C increases post EVAR regardless of the 
pre-operative status and regardless of peri-operative renal protection measures. 
Recent reports suggested the incidence of renal dysfunction following fenestrated 
EVAR is 10-30%.(91, 98, 165) These results were based on measuring sCr and CrC. 
To the best of our knowledge, this paper is the first to assess renal function following 
fenestrated EVAR using Cyst C. The increase in Cyst C at 24 hours, experienced in 
the current study, could be explained by the increased contrast dose and catheter 
and wire manipulations within the renal arteries during fenestrated EVAR. At one 
month, the fall in Cyst C may be due to the renal arteries stent-grafts improving renal 
perfusion, but this effect is not apparently maintained at 6 and 12 months. 
Unfortunately, none of the patients was followed up with CT scan at 12 months (as is 
our practice) so we cannot comment on the state of the renal vasculature. 
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8.5 Conclusion: 
The present study demonstrates that Cyst C increases significantly following 
standard and fenestrated EVAR and this is matched by similar results in sCr and 
eGFR. Cyst C continues to increase at 1, 6 and 12 months following the operation, 
which was not the case with sCr and eGFR, suggesting that it is capable of detecting 
progressive deterioration in renal function up to one year following EVAR. This may 
encourage the use of Cyst C in patients following EVAR to monitor the renal 
function. Longer follow up is required to determine the relationship between 
increased Cyst C and clinical renal outcome in this group of patients. 
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Chapter 9 
Summary and Conclusion 
9.1 Summary:  
All EVAR procedures were undertaken uneventfully with complete exclusion of the 
aneurysm sac as confirmed by the completion angiography and post procedure CT. 
Three patients required re-intervention for unilateral claudication due to graft limb 
stenosis. Two other patients developed asymptomatic type II endoleak, which were 
treated conservatively. All OARs were undertaken uneventfully without major 
complications and none of the patients required re-intervention.  
The median pre-operative PF1+2 and TAT were significantly higher than normal. At 
24 hours and one month, there was no significant change in PF1+2 from the 
baseline level and stayed above normal levels. There was significant drop in PF1+2 
at six months and 12 months (p<0.001). TAT increased significantly at 24 hours 
post-operatively. This was followed by return to the pre-operative level at one, six 
and 12 months post-operatively. (Figures 3 & 4) TAT and PF1+2 did not correlate at 
any time point. 
The median PAI, t-PA antigen and activity were within normal values. PAI increased 
significantly at 24 hours. This was followed by significant drop at one and six months. 
At 12 months, there was a significant increase in PAI to return to the per-operative 
level. t-PA antigen increased significantly at 24 hours and then returned to the 
baseline level at one month. This was followed by significant reduction at six months 
and return back to pre-operative values at 12 months. There was no change in t-PA 
activity at 24 hours. This was followed by significant increase at one and six months 
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and return to pre-operative level at 12 months. (Figures 5, 6 & 7) PAI activity 
correlated significantly with t-PA antigen at all time points. 
sP-selec was subnormal pre-operatively with no significant change at 24 hours post-
operatively. At one month, there was significant elevation which remained high at six 
months. There was a significant drop at 12 months from the level of six months, 
however, the median value was higher than pre-operative level. (Figure 8) 
Aneurysm size did not correlate with coagulation, fibrinolytic or inflammatory markers 
pre or post-operatively.  
PF1+2 was significantly higher in patients with AAA pre-operatively in comparison to 
the AMC group. Post-EVAR and post-OAR were significantly lower than pre-
operative level. PF1+2 post-EVAR was not significantly different from post-OAR and 
both were not significantly different from AMC. The median levels of TAT in the four 
groups were higher than the normal range. However, there was no statistical 
significance between the four groups. (Figure 11 & 12) 
PAI activity did not differ in patients with AAA pre-operatively from AMC and one 
year post-EVAR. However, it was significantly higher post-OAR when compared to 
pre-operative level. t-PA antigen was within the normal range with no significant 
difference between the four groups. (Figure 13 & 14) 
The inflammatory response in patients with AAA pre-operatively was higher than 
AMC. No significant difference was found between post-EVAR and post-OAR 
groups. (Figure 15) 
Cyst C increased significantly at all time points when compared to the pre-EVAR 
value. sCr increased significantly at 24 hours with no significant change at any other 
time points. eGFR showed a significant drop at 24 hours and remained unchanged 
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for the rest of the study period. Changes in Cyst C, sCr and eGFR at 24 hours, 1, 6 
and 12 months are shown in Figures 16, 17 & 18. 
Patients with pre-existing renal impairment had significantly higher Cyst C and sCr 
and lower eGFR at all time points. In patients with normal pre-operative sCr, there 
was a significant increase at 24 hours and a trend toward an increase at 6 months. 
(Figure 19). 
Cyst C increased significantly in patients who had standard EVAR at the four time 
points post-operatively. In patients who had F-EVAR, there was a significant 
increase in Cyst C at 24 hours, no significant change at one month and a significant 
increase at 6 and 12 months. (Figure 21) 
The present study confirms that patients with AAA exhibit a hyper-coagulable state 
compared to AMC. The high levels of PF1+2 and TAT encountered in this study may 
indicate excess thrombin production and neutralization respectively. The increase in 
PF1+2 pre-operatively was related to AAA, while thrombin neutralization is not 
related to AAA and may be related to other factors like age, atherosclerosis and 
smoking. There was normalization of thrombin generation at one year post EVAR. 
Normal fibrinolysis was found in patients with AAA. This represents relative hypo-
fibrinolysis as you would expect increased fibrinolysis secondary to increased 
thrombin generation. 
The significant increase in platelet activity may justify giving dual anti-platelet therapy 
to patients following EVAR especially during the first year after the operation.  
The results of this study showed that inflammatory response may be related to the 
extent of the aneurysm rather than the size.  
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Removal (as in OAR) or exclusion (as in EVAR) of the intra-aneurysm thrombus from 
the circulation resulted in correction of the inflammatory and pro-coagulant drive 
found in patients with AAA. 
We found that one year following EVAR and OAR the coagulation mechanism and 
the inflammatory response are similar and not different from the AMC. 
EVAR was associated with significant increase in the level of Cyst C suggesting 
renal glomerular injury. This increase started 24 hours post-operatively and 
continued for 12 months.  
Patients with high sCr pre-operatively did not have significant changes in sCr levels 
post-operatively. Cyst C increased post EVAR regardless of the pre-operative status. 
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9.2 Conclusion:  
AAA is associated with a significant hyper-coagulable and hypo-fibrinolytic state. 
This is corrected one year following EVAR and OAR. The unchanged thrombin 
production and increased thrombin neutralization experienced on the first post-
operative day may be protective at the early stages following EVAR. The increase in 
thrombin generation reported previously in the immediate peri-operative period after 
EVAR and OAR does not continue on the medium term. The normalization of 
thrombin generation and fibrinolytic response one year after the operation may 
represent a decrease in the incidence of thrombo-embolic events that is high in 
patients with AAA. 
Following EVAR, dual anti-platelet therapy may be advisable to counteract the 
increase in platelet activity experienced during the first post-operative year.   
Cyst C increases significantly following standard and fenestrated EVAR and this is 
matched by similar results in sCr and eGFR. Cyst C continues to increase at 1, 6 
and 12 months following the operation, which was not the case with sCr and eGFR, 
suggesting that it is capable of detecting progressive deterioration in renal function 
up to one year following EVAR. This may encourage the use of Cyst C in patients 
following EVAR to monitor the renal function.  
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Chapter 10 
Future work 
10.1 Long term changes in coagulation and fibrinolysis: 
The current study is the first report to describe normalization of thrombin generation 
detected one year following EVAR. The combination of no increase in thrombin 
generation and increased thrombin neutralization following EVAR may be protective 
against cardiovascular complications and thrombo-embolic disorders in this group of 
patients. However, very little, if any, is known about the changes in coagulation and 
fibrinolysis beyond one year following EVAR. Longer follow up and investigation is 
recommended to find out whether the correction of coagulopathy is maintained at the 
long term. If the correction of the coagulopathy is lost, it is important to find out the 
relation of these changes with cardiovascular morbidity and mortality.  
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10.2 Effect of endoleak on haemostatic markers: 
Only two patients developed type II endoleak (6.89%). This would lead to leak of the 
blood flow, albeit low and slow, back to the aneurysm sac and in contact with the 
mural thrombus. In theory, this could lead to recurrence of the hyper-coagulable 
state found pre-operatively. Larger cohort of patients is needed to look into the effect 
of endoleak onto the coagulation and fibrinolysis drive following EVAR. It was 
previously calculated to have 20 patients to detect changes in the coagulation 
mechanism. This means that we need a cohort of >300 patients to get the required 
number of patients with endoleak to detect the change in haemostasis.  
However, the majority of endoleak is type II which is considered benign condition 
that does not require intervention unless there is sac expansion. Moreover, this type 
of endoleak could easily be identified by the non-invasive duplex ultrasound. The use 
of haemostatic markers, as non-invasive investigation, will be of great benefit in the 
cases of sac expansion in absence of radiological evidence of endoleak (e.g. type V 
endoleak or endotension).  
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10.3 Cyst C as marker of renal function:  
The current study is the first to show a significant increase in the level of Cyst C 
following EVAR, suggesting renal glomerular injury. Of the 29 patients, 25 showed a 
significant increase in Cyst C levels at 12-months. This increase started 24 hours 
post-operatively and continued for 12 months following the operation and was 
significantly higher than pre-operative values. This is matched by similar results in 
sCr and eGFR in the immediate post-operative period but not at one month post-
operatively. None of the patients required renal replacement therapy. Longer follow 
up is required to determine the relationship between increased Cyst C and clinical 
renal outcome in this group of patients. It is also needed to determine whether the 
Cyst C will continue to increase after 12 months.  
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Background: Endovascular aneurysm repair (EVAR) is associated with an improved perioperative mortality compared to
open surgical repair. This benefit may reflect reduced incidence of microvascular and macrovascular thrombotic
complications after EVAR.
Purpose: The purpose of this study was to review and compare the effects of abdominal aortic aneurysm (AAA), open
surgical repair, and EVAR on coagulation, fibrinolysis, and platelet activation.
Methods: AMEDLINE (1966-2010) and Cochrane library search for articles relating to the effects of AAA, open surgical
repair, and EVAR on hemostasis was performed utilizing and cross-linking terms such as clotting, fibrinolysis, AAA,
EVAR, and open surgical repair. Studies with a small cohort of patients (less than 7) or in which values of assessed
biomarkers were not included were rejected.
Results: AAA is associated with increased thrombin generation, activity, and fibrin turnover as evidenced by increased
plasma levels of thrombin-antithrombin III-complex (TAT), activated protein C-protein C inhibitor (APC-PCI),
fibrin-monomer-fibrinogen (FM-F), F1!2, fibrinogen, and D-dimer. The extent of hemostatic derangement correlates
with the volume of intraluminal thrombus. This procoagulant state is exaggerated in the immediate perioperative period
after both open surgical repair and EVAR, but is attenuated at medium-term follow-up although not normalized.
Conclusion: The resultant prothrombotic diathesis after open surgical repair and EVARmay account for the high level of
perioperative thrombotic complications. ( J Vasc Surg 2011;54:865-78.)
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Background: Abdominal aortic aneurysm (AAA) is associated with a prothrombotic diathesis that may increase the risk of
cardiovascular events. This diathesis is exacerbated in the short term by open aneurysm repair (OAR) and endovascular
aneurysm repair (EVAR). However, the effect of EVAR andOAR on coagulation and fibrinolysis in the medium and long
term is poorly understood. The purpose of this study was to investigate the medium-term effects of EVAR and OAR on
thrombin generation, neutralization, and fibrinolysis.
Methods: Prothrombin fragment (PF)1 ! 2, thrombin antithrombin (TAT) complex, plasminogen activator inhibitor
(PAI) activity, and tissue-plasminogen activator (t-PA) antigen were measured in eight age-matched controls (AMCs), 29
patients with AAA immediately before (preoperatively) and 12 months after EVAR (post-EVAR), and in 11 patients at
a mean of 16 months after OAR (post-OAR).
Results: Preoperatively, PF1 ! 2 levels were significantly higher in patients with AAAs than in AMC. PF1 ! 2 levels
post-EVAR and post-OAR were significantly lower than preoperative values and similar to AMC. There was no
significant difference in TAT, PAI, or t-PA between AMC, AAA preoperatively, and post-EVAR. Post-OAR, PAI activity
was significantly higher than in preoperative patients.
Conclusions: AAA is associated with increased thrombin generation without upregulation of fibrinolysis. The prothrom-
botic, hypofibrinolytic diathesis observed in patients with AAA returns toward normal in the medium term after EVAR
and OAR, although there is a trend toward decreased fibrinolysis post-OAR. (J Vasc Surg 2013;57:103-7.)




Changes in thrombin generation, fibrinolysis,
platelet and endothelial cell activity, and
inflammation following endovascular abdominal
aortic aneurysm repair
Mohamed F. Abdelhamid, MSc, MRCSEd,a,b Robert S. M. Davies, MRCS,a,b
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Background: Abdominal aortic aneurysm (AAA) is a chronic inflammatory condition associated with a prothrombotic,
hypofibrinolytic diathesis that may increase the risk of cardiovascular events. The effect of endovascular aneurysm repair
(EVAR) on this prothrombotic diathesis is not fully understood, especially over the medium and long term. A better
understanding of these postintervention changes may improve the risk of cardiovascular complications in the long term.
The purpose of this study was to examine thrombin generation, fibrinolysis, platelet and endothelial activation, and the
inflammatory response during the 12 months following EVAR.
Methods: Twenty-nine patients (mean age, 76.9 years) undergoing EVAR for AAA (mean diameter 6.9 cm) had
prothrombin fragment (PF) 1 ! 2, thrombin-antithrombin complex (TAT), plasminogen activator inhibitor (PAI)
activity, tissue plasminogen activator (t-PA) activity and antigen, soluble P- and E-selectin, and highly sensitive C-reactive
protein (hsCRP) measured before and at 24 hours, and 1, 6, and 12 months after surgery.
Results: PF1 ! 2 were markedly elevated prior to EVAR and remained so at 24 hours and 1 month, but had decreased
significantly at 6 and 12 months. TAT was also elevated prior to EVAR and increased still further by 24 hours, but fell
to below baseline levels thereafter. PAI activity and t-PA antigen were normal prior to EVAR, increased significantly at
24 hours, and then fell to baseline levels. t-PA activity was only detectable at 1 and 6 months; there was a significant rise
in soluble P- and E-selectin after EVAR, which was sustained for 12 months. hsCRP increased transiently in response to
EVAR but returned to preoperative levels by 1 month.
Conclusions: The prothrombotic, hypofibrinolytic diathesis associated with AAA is normalized 12 months after EVAR.
This beneficial systemic effect of EVAR for AAA disease may help protect patients against future thromboembolic
cardiovascular events. ( J Vasc Surg 2012;55:41-6.)





Assessment of Renal Function by Means
of Cystatin C Following Standard and
Fenestrated Endovascular Aneurysm Repair
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and Andrew W. Bradbury,2 Birmingham, United Kingdom
Background: Cystatin C (Cyst C) is more sensitive marker for early renal injury. However,
serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) are still used as the stan-
dard renal markers after endovascular aortic aneurysm repair (EVAR). The goal of this study
was to compare the efficacy of Cyst C, sCr, and eGFR as markers of renal function after EVAR.
Patients and Methods: This study examined 29 patients (27 men) with a mean age of 76.9
years (range, 55e89 years) undergoing standard (n ¼ 19) and fenestrated (n ¼ 10) EVAR for
abdominal aortic aneurysm (AAA) of mean diameter 6.9 cm (range, 5.5e10 cm). Cyst C and
sCr were measured and eGFR calculated before and 1 day and 1, 6, and 12 months after EVAR.
Results: At 24 hours after procedure, a significant increase in Cyst C (P < 0.005) and sCr (P ¼
0.028) and significant decrease in eGFR (P ¼ 0.04) were seen. Cyst C continued to increase
and was significantly higher at 1 (P< 0.002), 6 (P< 0.005), and 12 (P< 0.005) months compared
with baseline. By contrast, sCr and eGFR did not show any significant change at 1, 6, and 12
months from the baseline level. Cyst C increased significantly postoperatively regardless of the
baseline renal function. None of the patients required renal replacement therapy.
Conclusions: EVAR is associated with a significant increase in Cyst C starting 24 hours after
the procedure and is maintained for 12 months. sCr and eGFR only show significant change at
24 hours and therefore may underestimate long-term renal damage after EVAR.





